

Almirall, S.A. and Subsidiaries
(Almirall Group)

Consolidated Financial Statements for the year ending on 31 December 2025, prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)
CONSOLIDATED BALANCE SHEET AS OF DECEMBER 31

(Thousands of Euros)

ASSETS	Note	31/12/2025	31/12/2024
Goodwill	8	315,966	315,966
Intangible assets	9	894,332	936,967
Right-of-use assets	10	40,776	43,586
Property, plant and equipment	11	168,864	153,790
Financial assets	12	22,690	16,350
Deferred tax assets	23	180,523	188,860
NON-CURRENT ASSETS		1,623,151	1,655,519
Stocks	14	178,132	171,783
Trade and other receivables	15	158,470	151,444
Current tax assets	23	17,459	21,632
Other current assets	5-h)	21,103	18,987
Current financial investments	12	1,050	201
Cash and cash equivalents	13	337,769	377,097
CURRENT ASSETS		713,983	741,144
TOTAL ASSETS		2,337,134	2,396,663

LIABILITIES AND EQUITY	Note	31/12/2025	31/12/2024
Subscribed capital	16	25,774	25,616
Share premium	16	596,078	581,874
Legal reserve	16	4,275	4,275
Other reserves	16	811,853	838,929
Valuation adjustments and other adjustments	16	(28,475)	(31,867)
Translation differences	16	31,475	59,408
Profit (loss) for the year		46,154	10,147
EQUITY		1,487,134	1,488,382
Deferred income	17	25,633	4,485
Financial debts	19	270,035	332,993
Non-current liabilities from leasing	10	34,508	37,521
Deferred tax liabilities	23	60,639	64,992
Retirement benefit obligations	20	52,109	58,581
Provisions	21	7,931	8,447
Other non-current liabilities	19	48,506	47,838
NON-CURRENT LIABILITIES		499,361	554,857
Financial debts	18	13,656	14,373
Current liabilities for leasing	10	7,775	7,061
Trade payables	19	193,853	186,525
Current tax liabilities	23	31,009	42,511
Other current liabilities	19	104,346	102,954
CURRENT LIABILITIES		350,639	353,424
TOTAL LIABILITIES AND EQUITY		2,337,134	2,396,663

Notes 1 to 34 explained in the Notes to the Consolidated Financial Statements and the Annex are an integral part of the consolidated financial statements for the year ending on 31 December 2025.

Almirall, S.A. and Subsidiaries (Almirall Group)

CONSOLIDATED INCOME STATEMENT

FOR THE YEAR ENDING ON DECEMBER 31

(Thousands of Euros)

	Note	Fiscal year 2025	Fiscal year 2024
Net turnover	22	1,108,084	985,721
Other Income	22	6,448	4,906
Operating income		1,114,532	990,627
Work carried out on fixed assets	9	28,078	20,354
Supplies	22	(264,549)	(238,395)
Staff costs	22	(263,784)	(234,931)
Depreciation	9, 10 & 11	(151,183)	(139,084)
Net change in valuation adjustments	22	458	(695)
Other operating expenses	22	(390,302)	(348,265)
Net gains (losses) on disposal of assets	22	(199)	(3,494)
Impairment losses on property, plant and equipment, intangible assets and goodwill	9 & 22	-	(10,031)
Operating profit		73,051	36,086
Financial income	22	6,848	7,652
Financial expenses	22	(16,948)	(15,658)
Exchange rate differences	22	(65)	(1,105)
Valuation gain on financial instruments	18 & 22	11,562	(477)
Financial result		1,397	(9,588)
Earnings before tax		74,448	26,498
Corporate income tax	23	(28,294)	(16,351)
Net profit for the year attributable to the Parent Company		46,154	10,147
Earnings / (Loss) per Share (Euros):	26		
A) Basic		0.22	0.05
B) Diluted		0.22	0.05

Notes 1 to 34 explained in the Notes to the Consolidated Financial Statements and the Annex are an integral part of the consolidated financial statements for the year ending on 31 December 2025.

Almirall, S.A. and Subsidiaries (Almirall Group)
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDING ON DECEMBER 31
(Thousands of Euros)

	Note	Fiscal year 2025	Fiscal year 2024
Profit (loss) for the year		46,154	10,147
Other comprehensive income:			
<i>Items not to be reclassified to income</i>			
Retirement benefit obligations	20	5,769	1,606
Income tax on items that will not be reclassified	23	(2,377)	(268)
Others		-	-
Total items not to be reclassified to income		3,392	1,338
<i>Items that can be reclassified subsequently to profit or loss</i>			
Other changes in value		-	-
Foreign currency translation differences	16	(27,933)	15,581
Total items that can be reclassified subsequently to profit or loss		(27,933)	15,581
Other comprehensive income for the fiscal year, net of tax		(24,541)	16,919
Total comprehensive income for the year		21,613	27,066
Attributable to:			
- Owners of the parent company		21,613	27,066
- Non-controlling interests		-	-
Total comprehensive income attributable to owners of the parent company derived from:			
- Continuing operations		21,613	27,066
- Discontinued operations		-	-

Notes 1 to 34 explained in the Notes to the Consolidated Financial Statements and the Annex are an integral part of the consolidated financial statements for the year ending on 31 December 2025.

Almirall, S.A. and Subsidiaries (Almirall Group)
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDING ON DECEMBER 31
(Thousands of Euros)

	Note	Subscribed capital	Share premium	Legal reserve	Other reserves			Other comprehensive income		Profit attributable to the Parent Company	Equity
					Other reserves of the Parent Company	Treasury shares of the Parent Company	Consolidated reserves	Valuation adjustments to equity	Translation differences		
Balance as at 1 January 2024	16	25,127	545,866	4,275	861,193	(2,858)	57,649	(33,205)	43,827	(38,474)	1,463,400
Distribution of profits		-	-	-	(60,154)	-	21,680	-	-	38,474	-
Dividends	25	489	36,008	-	(39,785)	-	-	-	-	-	(3,288)
Treasury shares of the Parent Company	16	-	-	-	1,127	77	-	-	-	-	1,204
Total comprehensive income for the year		-	-	-	-	-	-	1,338	15,581	10,147	27,066
Balance as at 31 December 2024	16	25,616	581,874	4,275	762,381	(2,781)	79,329	(31,867)	59,408	10,147	1,488,382

	Note	Subscribed capital	Share premium	Legal reserve	Other reserves			Other comprehensive income		Profit attributable to the Parent Company	Equity
					Other reserves of the Parent Company	Treasury shares of the Parent Company	Consolidated reserves	Valuation adjustments to equity	Translation differences		
Balance as at 1 January 2025	16	25,616	581,874	4,275	762,381	(2,781)	79,329	(31,867)	59,408	10,147	1,488,382
Distribution of profits		-	-	-	121,657	-	(111,510)	-	-	(10,147)	-
Dividends	25	158	14,204	-	(40,559)	-	-	-	-	-	(26,197)
Treasury shares of the Parent Company	16	-	-	-	2,488	848	-	-	-	-	3,336
Total comprehensive income for the year		-	-	-	-	-	-	3,392	(27,933)	46,154	21,613
Balance as at 31 December 2025	16	25,774	596,078	4,275	845,967	(1,933)	(32,181)	(28,475)	31,475	46,154	1,487,134

Notes 1 to 34 explained in the Notes to the Consolidated Financial Statements and the Annex are an integral part of the consolidated financial statements for the year ending on 31 December 2025.

Almirall, S.A. and Subsidiaries (Almirall Group)

CONSOLIDATED CASH FLOW STATEMENT

FOR THE YEAR ENDING ON DECEMBER 31

(Thousands of Euros)

	Note	Fiscal year 2025	Fiscal year 2024
Cash Flow			
Earnings before tax		74,448	26,498
Depreciation	9, 10 & 11	151,183	139,084
Valuation adjustments for impairment	9 & 22	-	10,031
Net gains (losses) on disposal of assets	22	199	3,494
Financial income	22	(6,848)	(7,652)
Financial expenses	22	16,948	15,658
Exchange rate differences	22	65	1,105
Changes in fair value of financial instruments	18 & 22	(11,562)	477
Incorporation of deferred income	17	20,000	-
Allocation of deferred income	17	(2,927)	(2,938)
Change in fair value of Covis Pharma financial assets	12 & 22	-	(2)
		241,506	185,755
Adjustments for changes in working capital:			
Change in stocks	14	(7,653)	(3,531)
Change in trade and other receivables	15	(26,124)	(4,722)
Change in trade payables	19	9,376	1,046
Change in other current assets		(3,180)	(3,110)
Change in other current liabilities		(1,524)	10,391
Adjustments for changes in other non-current items:			
Other non-current assets and liabilities		(2,315)	(877)
		(31,420)	(803)
Cash flow from taxes:			
		(35,627)	(24,185)
Net cash flows from operating activities (I)		174,459	160,767
Cash flow from investment activities			
Interest received		6,202	6,823
Investments:			
Intangible assets	9 & 19	(102,398)	(131,596)
Property, plant and equipment	11	(34,910)	(29,835)
Financial assets	12	(1,319)	(237)
Divestments:			
Receivables linked to the contract with Covis/AstraZeneca	12	5,662	13,152
Other non-current assets		27	1,653
Net cash flows from investment activities (II)		(126,736)	(140,040)
Cash flow from financing activities			
Interest payable	18	(11,462)	(10,537)
Equity instruments:			
Dividends paid	25	(26,197)	(3,288)
Acquisition/Disposal of own equity instruments	16	1,311	539
Financial instruments:			
Issuance of bonds and other marketable securities	18	245,000	-
Repayment of bonds and other marketable securities	18	(300,000)	-
Repayment of debts with credit institutions	18	(10,000)	(10,000)
Finance lease payments	11	(9,571)	(8,582)
Others		23,868	284
Net cash flows from financing activities (III)		(87,051)	(31,584)
Net change in cash and cash equivalents (I+II+III)		(39,328)	(10,857)
Cash and cash equivalents at the start of the fiscal year		377,097	387,954
Cash and cash equivalents at the end of the fiscal year		337,769	377,097

Notes 1 to 34 explained in the Notes to the Consolidated Financial Statements and the Annex are an integral part of the consolidated financial statements for the year ending on 31 December 2025.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

1. Activity of the Group

Almirall, S.A. is the Parent Company of a Group of companies (hereinafter, the Almirall Group), which is made up of the subsidiaries listed in the Appendix attached to these annual financial statements, the corporate purpose of which consists basically of the purchase, manufacture, storage, marketing, and mediation in the sale of pharmaceutical specialities and products, as well as of all types of raw materials used in the preparation of such pharmaceutical specialities and products.

Accordingly, the Parent Company's corporate purpose also includes:

- The purchase, manufacture, storage, marketing, and mediation in the sale of cosmetics and of chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food use, as well as of all kinds of instruments, complements and accessories for the chemical, pharmaceutical and clinical industry.
- Research on active chemical and pharmaceutical ingredients and products.
- The purchase, sale, rental, subdivision, and development of plots, land and estates of any nature, with the option of choosing to construct or dispose of these, in full, in part, or under the horizontal property regime.
- The provision of prevention services for the undertakings and companies participating in the company pursuant to Art. 15 of Royal Decree 39/1997, of 17 January, which establishes the Prevention Services Regulations, and implementing regulations. This activity may be regulated and carried out jointly for related and participating companies pursuant to Art. 21 of the aforementioned legal text. It is expressly stated that, according to the law, this activity does not require administrative authorisation. This activity may be subcontracted to other specialised entities pursuant to Art. 15 of Royal Decree 39/1997.
- Directing and managing the Parent Company's participation in the share capital of other entities through the appropriate organisation of human and material resources.

Pursuant to the Parent Company's articles of association, the aforementioned corporate purpose may be pursued, in whole or in part, directly by the Parent Company itself or indirectly through shareholding or equity interests, or any other rights or interests in companies or other types of entities, with or without legal personality, with registered office in Spain or abroad, which engage in activities identical or similar to those included in the corporate purpose of the Parent Company.

Almirall, S.A. is a public limited company listed on the Spanish Stock Exchanges and included in the Spanish continuous market (SIBE). Its registered office is located at Ronda General Mitre, 151, Barcelona (Spain). Its headquarters is located at the same address (Ronda General Mitre, 151).

2. Basic principles of presentation of the consolidated financial statements and principles of consolidation

a) Financial reporting regulatory framework applicable to the Group

The consolidated financial statements of the Almirall Group for the year ending on 31 December 2025, which have been obtained from the accounting records kept by the Parent Company and by the other entities comprising the Group, were prepared by the Parent Company's Board of Directors on 20 February 2026.

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union, taking into consideration all mandatory accounting principles and rules and valuation criteria, as well as in accordance with the Spanish Code of Commerce, the Spanish Capital Companies Act and all other applicable commercial legislation, so that they give a true and fair view of the equity and financial position of the Almirall Group on 31 December 2025 and of the results of its operations, of the changes in consolidated equity and of the changes in other consolidated comprehensive income and of the consolidated cash flows that have taken place in the Group in the fiscal year ending on that date.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

The consolidated financial statements have been prepared using the historical cost method, modified with respect to the recording of financial instruments at fair value, as required by the accounting regulations.

However, given that the accounting principles and valuation criteria applied in the preparation of the Group's consolidated financial statements for 2025 may differ from those used by some of the Group companies, the necessary adjustments and reclassifications have been made in the consolidation process in order to standardise such principles and criteria and to bring them into line with International Financial Reporting Standards (IFRS).

The Group's consolidated financial statements for 2024 were approved by the Parent Company's General Shareholders' Meeting held on 9 May 2025. These consolidated financial statements of the Group for fiscal year 2025 are pending approval by the Parent Company's General Shareholders' Meeting. Nevertheless, the Parent Company's Board of Directors expects that they will be approved without any changes.

b) Adoption of International Financial Reporting Standards

The consolidated financial statements of the Almirall Group for the year ending on 31 December 2005 were the first to be prepared in accordance with International Financial Reporting Standards established in Regulation (EU) No. 1606/2002 of the European Parliament and of the Council of 19 July 2002. In Spain, the obligation to present consolidated financial statements under an EU-adopted IFRS basis was also regulated in Final Provision Eleven of Law 62/2003, of 30 December, on fiscal, administrative and social measures.

The main accounting policies and valuation standards adopted by the Almirall Group are presented in Note 5.

With respect to the application of IFRS, the main choices made by the Almirall Group are as follows:

- To present the consolidated balance sheet by classifying its items as current and non-current.
- To present the consolidated income statement by classifying its items by type.
- To present the consolidated cash flow statement using the indirect method.
- To present income and expenses in two separate statements: a consolidated income statement and a consolidated comprehensive income statement.

As detailed below, new accounting standards (IAS/IFRS) and interpretations (IFRIC) entered into force in 2025. Furthermore, as of the preparation date of these consolidated financial statements, new accounting standards (IAS/IFRS) and interpretations (IFRIC) have been published and are expected to come into force for accounting periods beginning on or after 1 January 2026.

Mandatory standards, amendments and interpretations for all fiscal years beginning on or after 1 January 2025:

- No exchange of currencies - Amendment to IAS 21.

Standards, amendments and interpretations that have not yet entered into force but may be adopted in advance:

- IFRS 18 Presentation and Disclosure in Financial Statements – Replacing IAS 1, effective 1 January 2027.
- Classification and Measurement of Financial Assets - Amendments to IFRS 9
- Contracts referencing nature-dependent electricity - Amendments to IFRS 9 and IFRS 7
- Subsidiaries without Public Accountability: Disclosures - Amendments to IFRS 19

As indicated above, the Group has not considered the early application of the Standards and interpretations detailed above and, in any case, the Group is analysing the impact that these new standards/amendments/interpretations may have on the Group's consolidated financial statements, should they be adopted by the European Union.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

c) Comparison of information

There have been no significant changes in the composition of the Group that would significantly affect the comparability of the consolidated balance sheet figures as of 31 December 2025 with those of 31 December 2024. The same is true of the comparability of the figures in the consolidated income statement for the fiscal year ending on 31 December 2025 with those for the fiscal year ending on 31 December 2024.

d) Functional currency

These consolidated financial statements are presented in euros, since this is the currency of the main economic environment in which the Group operates. Other relevant currencies in the Group's operations are the US dollar, the pound sterling and the Swiss franc, among others (see Note 22).

e) Estimates made

The consolidated income and the determination of consolidated equity are sensitive to the accounting principles and policies, valuation criteria and estimates used by the Parent Company's Board of Directors in preparing the consolidated financial statements. In the consolidated financial statements of the Group for the fiscal year ending on 31 December 2025, estimates made by the Group's management and by the management of the consolidated entities were occasionally used and subsequently ratified by the Parent Company's Board of Directors in order to quantify certain assets, liabilities, income, expenses and obligations that are reported in the financial statements. Basically, these estimates refer to:

- Impairment losses on certain items from property, plant and equipment, intangible assets and goodwill arising from the non-recoverability of the carrying amount recorded for these assets (Notes 5-d), 7-b), 8 and 9).
- The useful life of intangible assets and of the property, plant and equipment (Notes 5-b) and 5-c)).
- The evaluation of the recoverability of deferred tax assets (Note 23).
- The fair value of certain unquoted financial assets (Note 5-k) and 12).
- Precise assumptions for determination of the actuarial liability for the retirement benefit obligations in coordination with an independent expert (Note 5-m)).

Although these estimates were made on the basis of the best information available on 31 December 2025 about the analysed events, it is possible that events that take place in the future might make it necessary to change these estimates in subsequent years (upwards or downwards), which, in accordance with IAS 8, would be done prospectively, thereby recognising the effects of the change in estimate on the corresponding consolidated income statement.

3. Principles of consolidation and changes in the scope of consolidation

a) Principles of consolidation

The accompanying consolidated financial statements have been prepared from the accounting records of Almirall, S.A. and of the companies controlled by it. The financial statements of the latter are prepared by the Board of Directors or the Directors of each company.

Subsidiaries are all companies over which the Group has control. The Group controls an entity when it is exposed to, or has the right to variable returns from its involvement with the investee entity and has the ability to influence those returns through the power to direct the entity's relevant activities. Subsidiaries are consolidated from the date on which control is transferred to the Group. They cease to be consolidated starting from the date on which control ceases.

The criteria followed to determine the consolidation method applicable to each of the companies comprising the Almirall Group have been of full consolidation, since these are companies in which the direct or indirect shareholding is greater than 50% and over which the Group exercises effective control due to the majority of votes in their representative and decision-making bodies. Consequently, all the significant balances and effects of transactions between consolidated companies have been eliminated in the consolidation process.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

The consolidation of the results generated by the companies acquired in the course of a fiscal year is carried out by including only those results for the period between the date of acquisition and the end of that fiscal year. Simultaneously, the consolidation of the results generated by the companies disposed of in a fiscal year is carried out by including only those results for the period between the start of the fiscal year and the date of disposal.

When necessary, the financial statements of subsidiaries are adjusted so that the accounting policies used are consistent with those used by the Group's Parent Company.

When the Group ceases to have control, any retained interest in the entity is revalued at fair value on the date that control is lost, with the change in the carrying amount recognised in the income. The fair value is the initial carrying amount for the purposes of subsequent accounting of the interest retained as an associated company, joint venture or financial asset. In addition, any amount previously recognised in other comprehensive income for that entity is recognised as if the Group had directly sold the related assets or liabilities. This could mean that amounts previously recognised in other comprehensive income are reclassified to the consolidated income statement.

In addition, the accompanying consolidated financial statements do not include the tax effect that might arise as a result of including the income and reserves generated by the subsidiaries in the equity of the Parent Company, since, pursuant to IAS 12 and given that the Parent Company controls the subsidiaries, it is considered that no transfers of reserves will be made that give rise to additional taxation and, if applicable, would not be relevant.

The Annex of these notes to the consolidated financial statements details the dependent companies included in the consolidation process, as well as the main information related to them.

Finally, at 31 December 2025 and 2024, two of the companies included in the scope of consolidation are considered inactive (Almirall Europa Derma, S.A. and Laboratorios Tecnobio, S.A.). There are no other companies that are outside the scope of consolidation.

b) Variations in the scope of consolidation

During the year ending 31 December 2025, the following change in the business composition of the Group occurred.

- On 13 August 2025, Almirall (Shanghai) Pharmaceutical Consulting Co., Ltd. was established, based in Shanghai (China), with an amount of 1 million yuan (equivalent to 119 thousand euros). This entity will be engaged in identifying and evaluating innovative licenses and development agreements that will strengthen the Group's pipeline. As of 31 December 2025, the capital is pending disbursement.

There were no changes in the corporate composition of the Group's scope during the year ended 31 December 2024.

4. Flexible dividend

When a dividend is approved, which may be settled in cash or through the issue of fully paid-up shares at the investor's option, i.e. remuneration with shares for a specific value, the Group recognises the corresponding liability by means of a charge to reserves equivalent to the fair value of the rights to be allotted shares at no charge. If the investor elects to subscribe for fully paid-up shares, the Group will recognise the corresponding capital increase. If the investor elects to collect the dividend, the Group will derecognise the liability by means of a credit to the cash paid.

At the preparation date of these consolidated financial statements, the Board of Directors of Almirall, S.A. has resolved to propose to the General Shareholders' Meeting the distribution of a dividend charged to unrestricted reserves in the amount of €40.8 million (equivalent to €0.19 per share). For the purposes of this dividend distribution, it is proposed that the "Flexible Dividend" shareholder remuneration system be used, which has already been applied in previous years (see Note 34).

5. Accounting criteria

The consolidated financial statements of the Group for the year ending on 31 December 2025 have been prepared by the Parent Company's Board of Directors in accordance with International Financial

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Reporting Standards (IFRS), as approved by the European Union pursuant to Law 62/2003 of 30 December.

The main valuation standards used to draw up these consolidated financial statements, in accordance with the International Financial Reporting Standards (IFRS) as adopted by the European Union, and also with the interpretations in force at the time when these consolidated financial statements were prepared, were as follows:

a) Goodwill

The Group applied the exception provided for in IFRS 1 “First-time Adoption of International Financial Reporting Standards” and therefore only business combinations carried out on or after 1 January 2004, the date of transition to IFRS-EU, have been accounted for using the acquisition method. Acquisitions of entities made prior to that date were recorded in accordance with the previous generally accepted accounting principles, after taking into account the necessary corrections and adjustments at the transition date.

The Group has applied IFRS 3 “Business Combinations” as revised in 2008 for transactions carried out on or after 1 January 2010.

In business combinations, the Group applies the acquisition method. The excess between the consideration given and the net amount of assets acquired and liabilities assumed, less the value assigned to non-controlling interests, is recorded as goodwill. The assets acquired and the liabilities assumed are recognised on the acquisition date at their fair value.

Goodwill is not amortised, but is tested for impairment on an annual basis or earlier if there are signs of a potential loss in the value of the asset. For these purposes, the goodwill resulting from the business combination is allocated to each of the Group’s cash-generating units (CGUs) or groups of CGUs that are expected to benefit from the synergies of the combination and the criteria referred to in section d) (impairment) of this Note are applied. After initial recognition, goodwill is measured at cost less accumulated impairment losses.

b) Intangible assets

Intangible assets are initially recognised at acquisition cost (separately or through a business combination) or at production cost and subsequently measured at their cost, when appropriate, minus their accumulated amortisation and any impairment losses.

All registered intangible assets have a finite useful life and are amortised on the basis thereof, applying criteria similar to those adopted for the amortisation of property, plant and equipment; and these criteria are basically equivalent to the following amortisation rates for the most standard assets (determined on the basis of the average years of estimated useful life of the various items):

	Years of life
Industrial property	10 – 15
Computer applications	3 – 6

In the case of intangible assets resulting from licensing and/or development agreements, their useful life is estimated on the basis of the commercial life of the acquired rights. Generally, this covers the period from product launch to expiry of the patent (at which point the entry of generics is foreseen, if applicable), always limited to the contractual period for which the rights are held. Note 9 details the useful lives of the main intangible assets.

The consolidated entities recognise any impairment loss on the carrying amount of these assets with a charge to "Impairment losses on property, plant and equipment, intangible assets and goodwill" in the consolidated income statement. The criteria for recognising the impairment losses of these assets and, when applicable, the reversal of impairment losses recorded in previous years, are similar to those applied for property plant and equipment (Note 5-d)).

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Development costs

i. Internal development

The costs of research activities are recognised as an expense in the period in which they are incurred.

Expenses incurred internally as a result of the development of new drugs by the Group are only recognised as assets if all of the following conditions are met or can be demonstrated:

- It is technologically possible to complete the production of the drug so that it can be made available for use or sale.
- There is an intention to complete the development of the drug in question for use or sale.
- There is capacity to use or sell the drug.
- The asset will generate economic benefits in the future. Among other things, the existence of a market for the drug that has been developed, or for the development itself, can be demonstrated; or, if it is to be used internally, then the usefulness of the development for the Group is proven.
- The availability of adequate technological, financial or other resources to complete the development, and to use or sell the drug resulting from the ongoing development.
- The expenditure attributable to this development until its completion can be reliably measured.

The development of new drugs is subject to a high degree of uncertainty, due to the long maturation period of the drugs (usually several years) and of the technological results obtained in the different testing phases of the development process. In any of the different phases of the development process, it may be necessary to abandon said development, either because the new drugs do not meet medical and regulatory standards, or because they do not meet profitability thresholds. For these reasons, the Group considers that the uncertainty is only overcome once the developed product is approved by the competent authorities in a relevant market. This is the moment from which the Group considers that the conditions for the capitalisation of development expenses have been met.

ii. Separate acquisition

The acquisition separately or through a business combination of an ongoing research and development project is always capitalised pursuant to Para. 25 of IAS 38, since the price paid for the acquisition reflects expectations about the probability that the future economic benefits of the asset will be realised by the Group; in other words, the price paid reflects the probability of success of the project. When the Group acquires intangible assets with payments contingent on future events, it recognises them using the aggregate cost model.

Development costs (internal and acquired) previously recognised as an expense will not be recognised as an asset in a subsequent fiscal year.

Industrial property

Patents, trademarks and licences for the production, marketing and/or distribution of products are initially recorded at acquisition cost (separately or through a business combination) and are amortised over the estimated useful lives of the products to which they relate.

In the case of licensing and/or development agreements, payments subject to the achievement of regulatory or commercial milestones are generally recognised at the time the milestone is met. They are therefore considered to be contingent assets until that time and are recognised as an increase in the cost of the intangible asset in question. In the case of commercial milestones (where the product is usually already on the market), the amortisation period is reduced to the remaining useful life of the original asset.

In the event that any milestone implied an improvement in the protection of intellectual property (i.e. reducing the risk of entry of generics, for example), the useful life would be re-estimated accordingly.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

In the case of non-contingent assets, the cost is recognised at the initial moment, and the consideration is measured at a value equivalent to the amortised cost of the liability to be disbursed in the future, discounted at a market rate of interest.

Computer applications

In this account, the Group records the acquisition and development of software, whether it is the implementation of new software or substantial improvements to existing software. Maintenance costs for computer applications are charged to the consolidated income statement for the year in which they are incurred.

c) Property, plant and equipment

Property, plant and equipment are valued at cost (determined by separate acquisition or acquisition through a business combination).

Replacements or renewals of entire items that increase the useful life of the related asset, or its economic capacity, are recorded as an increase in property, plant and equipment, and the replaced or renewed items are derecognised.

Periodic maintenance, upkeep and repair expenses are charged to income on an accrual basis as a cost for the year in which they are incurred.

Items in progress are transferred to property, plant and equipment in operation once they are ready to be put into operation.

The annual depreciation charges for property, plant and equipment are recognised in the consolidated income statement, and they are basically equivalent to the depreciation rates determined on the basis of the years of estimated useful life. The land on which buildings and other structures are built is considered to have an indefinite useful life and is therefore not depreciated.

Among property, plant and equipment, there are a number of environmental assets whose main purpose is minimising environmental impacts and protecting and improving the environment, including the reduction or elimination of future pollution from the Group's operations. The annual cost, as well as the investments and the carrying value at the close of each fiscal year, are detailed in Note 31.

The Group also has photovoltaic panels at some of its production facilities, to produce energy for self-consumption. These assets are valued, as any tangible asset, at the acquisition or production cost.

The average useful lives of the various items are detailed below:

	Years of useful life
Construction	33-50
Technical installations and machinery	6-12
Other facilities and tools	4-12
Laboratory furnishings and equipment	6-10
Information processing equipment	4-6
Transport equipment	5-6.25

The income resulting from the disposal or retirement of an asset is calculated as the difference between the proceeds of the sale and the carrying amount of the asset, and is recognised in the consolidated income statement.

d) Impairment of property, plant and equipment, intangible assets and goodwill

The Group reviews the carrying amounts of its property, plant and equipment and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If such an indication exists, then the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). If the asset does not generate cash flows on its own that are independent of other assets, then the Group calculates the recoverable amount of the cash-generating unit to which the asset belongs. Intangible assets for which amortisation has not commenced are tested

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

for impairment at least at the end of each fiscal year, and whenever there are indications of impairment prior to the end of each year.

The properties associated with the Group's production centres are not assigned to any specific cash-generating unit (hereinafter "CGU"), given that they are in common use by various CGUs, most of which do not have an assigned intangible asset or goodwill, wherefore they are not included in the carrying amount when tested for impairment. However, the related costs are allocated on a reasonable allocation basis to the various products, which are ultimately considered as CGUs for the purposes of the Group's impairment tests. Furthermore, there is no property whose use is specific for a single product or CGU.

These assets have not been tested for impairment because there were no indications of impairment. If there were any, an analysis of the value chain of the associated product (which is usually the most easily identifiable CGU) would have been performed to assess whether any tangible asset could be affected (e.g. a product being discontinued or withdrawn from the market).

The recoverable amount is defined as whichever is the greater of the following amounts: fair value less costs to sell; or the value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a discount rate that reflects the current market assessments of the time value of money (TVM) and that also reflects any risks specific to the asset for which the estimated future cash flows have not been adjusted. Value in use is calculated by applying both cash flows and an after-tax discount rate. The fact of using these variables (discount rate and cash flows) before or after taxes does not significantly change the result of the analysis conducted.

The discount rate used is reviewed periodically (at least every six months), and it takes into account various components that reflect the current macroeconomic environment, such as the cost of risk-free debt (usually associated with the cost of public debt of the territory concerned), the sector Beta and the risk premium by size.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, then the carrying amount of the asset (cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in the consolidated income statement.

Losses related to the impairment of the value of the CGU reduce the value of the goodwill assigned to the CGU and then to the other assets of the CGU, pro rata based on the carrying amount of each of the assets, with the limit for each of them being the higher of their fair value less costs of disposal, their value in use and zero.

When an impairment loss subsequently reverses (a circumstance not permitted in the case of goodwill), the carrying amount of the asset (CGU) is increased to the revised estimate of its recoverable amount. This increase is implemented in such a way, however, that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (CGU) in previous fiscal years. A reversal of an impairment loss is recognised immediately as income in the consolidated income statement, up to that limit.

In the case of goodwill, the impairment analysis, which is conducted at the intervals described in Note 5-a). In the event that an impairment loss on goodwill must be recognised, this loss is not reversible.

In general, the method that the Almirall Group uses for impairment tests, based on the value in use of assets assigned to the CGUs with goodwill, relies on the estimate of cash flow projections drawn from financial budgets approved by the Management, which cover an explicit minimum period of 5 years. Cash flows beyond the explicit period are extrapolated using negative perpetual growth rates (g), given that, due to the very nature of the sector, products tend to be replaced by new, innovative products in the long term or they see their price significantly reduced as a consequence of new treatments and/or entry by generics, and therefore permanent growth scenarios are not considered in the long term. This is also in line with IAS 36 on the guide for growth rates in financial projections.

For certain assets (such as products under development that are not yet depreciated), detailed financial projections that range from 10 to 18 years are used (depending on the expected useful life of the asset). A probability of the project's success is applied to these projections, and a residual income is estimated for the following years by applying a growth rate that depends on the type and age of the products, based on experience with the same.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Other intangible assets are tested for impairment only in those cases where there are indications of impairment and those that are in progress (normally products in the development stage).

The estimated financial projections for each cash-generating unit or asset consist of estimated after-tax net cash flows. The latter are determined, in turn, based on the estimated sales, gross margins and other expected costs for that cash-generating unit. The projections are based on reasonable and well-founded assumptions.

Cash flows are estimated based on the maturity cycle of the product, the size of the market (which depends on the type of disease and the level of diagnosis of the disease), the therapeutic characteristics of the product itself (based on the clinical value of the product, a market share percentage within the therapeutic area is estimated) and the expected reimbursement price. In this regard, faced with tougher macroeconomic environments, it is true that the governments of the different territories have incentives to limit healthcare spending (one part being the cost of financed medicines and treatments), but these cost containment measures can take different forms, such as the prevalence of alternative generic treatments, limiting the number of patients treated, unilateral price cuts for certain medicines, etc., so it is difficult to estimate without knowing the specific measures that may be applied, but even so the Group has some margin to adapt in many cases.

The key variables of the impairment tests performed by the Group largely reflect the sales trend for each of the different drugs, most of which are currently in the marketing phase, as well as the discount rates applied and the perpetual growth rate. Other assumptions, such as gross margin or cash flows, are not considered key due to showing less uncertainty:

- Regarding gross margin, the costs of sale of many of the products subject to impairment testing are fixed to supply contracts with the original licensees, usually at a percentage of the selling price of the products. It is therefore unusual for the cost of inflation to be passed on. Likewise, operating expenses associated with manufacturing represent a small part of the total product cost (e.g. supplies), and most of the products manufactured by the Group do not have any associated intangible asset.
- Regarding cash flows, in general the pharmaceutical sector is counter-cyclical, given that chronic and prescription treatments tend to have stable demand, and they neither benefit from nor are they harmed by favourable or recessionary macroeconomic scenarios.

In terms of sensitivity to the key assumptions, the Group's Management considers 10% to be a deviation range with sufficient headroom to absorb unexpected events beyond what is considered reasonable under normal business conditions, based on the retrospective analysis of past estimates.

As for the discount rate assumption and the perpetual growth rate assumption, half a point has been set as reasonable based on the increases experienced in recent years in the former case and a conservative assumption in the latter case.

The main assumptions used in the impairment tests and the sensitivity analysis for the years ending on 31 December 2025 and 2024 are detailed in Notes 8 and 9.

e) Leases

Leases are recognised as a right-of-use asset (including the respective liability) on the date when the leased asset is available for use by the Group, in accordance with the provisions established by IFRS 16. Each lease payment is allocated between the corresponding liability and the financial expense. The financial expense is charged to income over the term of the lease, so as to produce a constant periodic interest rate on the remaining balance of the liability for each year. The right-of-use asset is amortised on a straight-line basis over the useful life of the asset or the lease term, whichever of these is shorter.

Assets and liabilities arising from a lease are initially measured on a present value basis. The lease liabilities maintained by the Group include the net present value of the following lease payments:

- fixed payments (including payments that are fixed in essence) less any lease incentive receivable, and
- lease termination penalties, if the lease term reflects the tenant's exercise of that option.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be determined, then the incremental borrowing rate is used, which is the rate the lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment under similar terms and conditions.

The Group rents offices, machinery and transportation equipment. Leases are normally for fixed terms of 3 to 5 years, although they may have extension options as described below. Lease terms are negotiated on an individual basis and include a wide range of different terms and conditions. The lease agreements do not impose covenants, but the leased assets cannot be used as collateral for borrowings.

The only individually relevant leased asset is the Group's headquarters, the terms of which are described in Note 10.

Given the nature of right-of-use assets, the initial cost recognised is essentially composed of the initial valuation of the lease liability; as a general rule, the initial direct costs or recovery costs are not relevant. Likewise, there are no variable lease payments other than those that depend on a rate or charge.

Payments associated with short-term leases (12 months or less) and leases of low-value assets (computer equipment and small items of office furniture) are recognised, on a straight-line basis, as an expense in the consolidated profit and loss statement.

f) Stocks

Stocks are valued at acquisition or production cost, or net realisable value, whichever is lower. Production costs include direct material costs and, where applicable, direct labour costs and applicable manufacturing overheads, also including those costs incurred for transport of stocks to their present location, and current conditions at the point of sale.

Trade discounts, rebates obtained, and other similar items are deducted when determining the acquisition price.

The cost price is calculated using the weighted average method. Net realisable value represents the estimated selling price less all estimated costs of completion and costs to be incurred in the marketing, selling and distribution processes.

The Group evaluates the net realisable value of stocks at the end of the year and recognises the appropriate loss when they are overvalued. When the circumstances that previously led to the write-down no longer exist or when there is clear evidence of an increase in net realisable value due to a change in economic circumstances, the amount of the write-down is reversed.

Estimates are also made for the impairment of these assets due to obsolescence, mainly due to the expiry date of the different proprietary medicinal products (which ranges from 2 to 5 years for finished products) or due to slow turnover in cases where the estimated demand is insufficient to absorb the inventories within a reasonable period of time.

g) Trade receivables for sales and services

Trade receivables are recorded at their amortised cost. The recoverable amount is determined at each balance sheet date and is reduced, where appropriate, by any write-downs to cover balances in which there are circumstances that result in their classification as bad debts. The late payment faced by the Group is not significant and is mainly concentrated in pharmacies and hospitals that are dependent on national health systems (mainly due to budgetary constraints).

h) Other current assets

This section includes those payments made by the Group for which the corresponding service had not been received in full or in part by the end of the year, and whose execution will occur within the following twelve months. The main items included are the annual fees associated with software contracts (office software licenses, cloud access technologies, ERP, etc.), insurance premiums and initial payments related to research and development contracts linked to services, as well as annual fees for the regulatory maintenance of products in certain markets (such as the United States).

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

i) Cash and cash equivalents

Cash and cash equivalents in the consolidated balance sheet include cash on deposit with the Group, demand bank deposits and financial investments convertible into cash with a maturity not exceeding three months from the date of acquisition. In addition, for the purposes of the Consolidated Cash Flow Statement, only those that do not have significant penalties in the event of early cancellation (maintaining the maturity limit at no more than three months) are considered.

j) Financial instruments (excluding derivative financial instruments)

Financial assets and liabilities are recognised in the consolidated balance sheet when the Group becomes a party to the contractual provisions of the financial instrument.

Financial assets

Classification: pursuant to IFRS 9, the Group classifies its financial assets into the following measurement categories:

- those subsequently measured at fair value (either through other comprehensive income or through profit or loss), and
- those that are measured at amortised cost.

The classification depends on the entity's business model for managing financial assets and the contractual terms of the cash flows.

For assets measured at fair value, profits and losses must be recorded in income or in other comprehensive income. For investments in equity instruments that are not held for trading, this will depend on whether the Group had made an irrevocable choice at initial recognition to account for the equity investment at fair value through other comprehensive income.

Recognition and derecognition: regular-way purchases and sales of financial assets are recognised on the trade date, i.e., the date on which the Group commits to purchase or sell the asset. Financial assets are derecognised when the rights to receive cash flows from the financial assets expire or are transferred and the Group has substantially transferred all the risks and rewards incidental to ownership.

Valuation: in the case of financial assets that are not at fair value through profit or loss (FVTPL), at initial recognition the Group measures these assets at fair value plus transaction costs that are directly attributable to the acquisition of the financial asset. In contrast, the transaction costs of financial assets recorded at fair value through profit or loss (FVTPL) are recognised as an expense in the income statement.

Debt instruments

Subsequent valuation of debt instruments depends on the Group's business model for managing the asset and on the cash flow characteristics thereof. The Group currently has debt instruments that fall into the following valuation categories:

- Amortised cost: Assets held for collection of contractual cash flows, when those cash flows represent only payments of principal and interest, are measured at amortised cost. Interest income from these financial assets is included in interest income using the effective interest rate method. Any gain or loss arising on derecognition is recognised directly in the income statement for the fiscal year and is recorded in other gains / (losses) together with gains and losses due to exchange rate differences. Impairment losses are presented as a separate item in the income statement.
- Fair value through profit or loss: Assets that do not meet the criteria for amortised cost or fair value through other comprehensive income are recognised at fair value through profit or loss. A gain or loss on a debt investment that is subsequently recognised at fair value through profit or loss is recognised in income and is recorded net in the income statement within other gains/(losses) in the fiscal year in which it arises.

Equity instruments.

The Group subsequently values all investments in equity at fair value. When the Group's Management has elected to present gains and losses at fair value of equity investments in other comprehensive

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

income, then there is no subsequent reclassification of gains and losses in fair value to income following derecognition thereof. Dividends from such investments continue to be recognised in the profit for the fiscal year as other income when the company's right to receive the payments is established.

Changes in the fair value of financial assets at fair value through profit or loss are recognised in other gains / (losses) in the income statement, when applicable. Impairment losses (and reversals of impairment losses) on equity investments measured at fair value through other comprehensive income are not presented separately from other changes in fair value.

Impairment

The Group evaluates the expected credit losses associated with its assets prospectively at amortised cost and at fair value through other comprehensive income. The method used for impairment depends on whether there has been a significant increase in the credit risk.

For trade receivables, the Group applies the simplified approach permitted by IFRS 9, which requires that expected lifetime losses are recognised, starting from the initial recognition of the receivables, see Note 15 for further details.

Financial liabilities

Trade accounts payable are payment obligations for goods or services acquired from suppliers in the ordinary course of business. Trade accounts payable are classified as current liabilities if payments are due within one year or less (or due within the normal operating cycle, if this cycle is longer). Otherwise, they are presented as non-current liabilities.

Trade accounts payable are initially recognised at fair value and are subsequently measured at amortised cost using the effective interest rate method, when the maturity is greater than twelve months.

Financial debts are initially recognised at fair value less incurred transaction costs. Subsequently, financial debts are valued at amortised cost; any difference between the funds obtained (net of the costs necessary to obtain them) and the redemption value is recognised in the consolidated income statement during the term of the debt, in accordance with the effective interest rate method.

Fees paid to obtain credit facilities are recognised as debt transaction costs, whenever it is probable that some or all of the facility will be drawn down. In this case, fees are deferred until the amount is drawn down. To the extent that it is not probable that all or part of the credit line will be drawn down, the fee is capitalised as an advance payment for liquidity services and is amortised over the period of availability of the credit facility.

Financial debt is removed from the balance sheet when the obligation specified in the contract has been paid, cancelled or expired. The difference between the carrying amount of a financial liability that has been settled or transferred to another party and the consideration paid, including any asset transferred other than cash or the liability assumed, is recognised in income for the fiscal year as other financial income or expense.

Loans granted by public bodies with subsidised interest rates or with grace periods constitute a form of government assistance. Any granted loans of this sort are recognised based on the fair value of the financing received; the differences arising between that fair value and the nominal value of the financing received are treated as a subsidy (see Note 19-b)).

Classification of financial assets and liabilities as current and non-current

In the accompanying consolidated balance sheets, financial assets and liabilities are classified by their dates of maturity; in other words, those maturing in twelve months or less from the consolidated balance sheet date are classified as current, and those maturing in more than twelve months as non-current.

k) Derivative financial instruments

The Group's activities expose it mainly to exchange rate risks, due to the marketing of products through licensees and subsidiaries in countries with currencies other than the euro, but the Group is also exposed to interest rate risks due to the Parent Company's indebtedness (Note 32).

For the years ended 31 December 2025 and 2024, the only derivative financial instrument held by the Group is the Equity swap described in Note 18, which does not qualify for hedge accounting.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

In this case, the derivative is initially recognised at fair value and is subsequently remeasured at fair value at each reporting date. Changes in the fair value of any derivative instrument that does not qualify for hedge accounting are recognised immediately in profit or loss and are included under "Valuation gains of financial instruments" in the consolidated income statement.

The entire fair value of a derivative is classified as a non-current asset or liability if the remaining maturity of the hedged item is greater than 12 months, and as a current asset or liability if the remaining maturity of the hedged item is less than 12 months.

l) Provisions and contingencies

When preparing the consolidated financial statements, the Parent Company's Board of Directors distinguishes between:

- Provisions: credit balances covering obligations existing at the consolidated balance sheet date derived from past events, which may give rise to outflows of financial resources that are of a specific nature but of uncertain amount and/or timing, and
- Contingent liabilities: possible obligations derived from past events that will become manifest only if one or more future events beyond the control of the consolidated entities occurs or fails to occur (Note 27-b).

The Group's consolidated financial statements include all significant provisions with regards to which it is considered more likely than not that the obligation will have to be settled. Contingent liabilities that do not result from a business combination are not recognised and are listed in Note 27.

Provisions, which are quantified by taking into consideration the best information available on the consequences of the event that gives rise to them and are re-estimated at the end of each reporting period, are used to address the specific, probable risks for which they were originally recognised, and are reversed, in whole or in part, when these risks disappear or decrease. They include the following legal proceedings and claims:

Ongoing legal proceedings and/or claims

The Group's activities fall within a highly regulated sector (health legislation, intellectual property, etc.), which increases its exposure to potential lawsuits arising from its business activities.

The claims and litigation to which the Group is subject are generally complex, meaning that the evolution thereof can be highly uncertain, both as regards the probability of an outcome detrimental to the Group's interests and as regards the estimate of potential future disbursements to be made. As a consequence, it is necessary to use judgements and estimates, counting on the support of the relevant legal consultants.

At year-end 2025 and 2024, various legal proceedings and claims were in progress against the Group, arising from its normal course of business. Both the Parent Company's legal consultants and its Board of Directors consider that the provisions recorded are sufficient and that the conclusion of these proceedings and claims will not have a significant impact on the consolidated financial statements for the years in which they are closed.

m) Cost of retirement benefits (or post-employment benefits)

The subsidiaries Almirall Hermal, GmbH, Almirall AG and Polichem, S.A. have obligations for retirement benefits (or post-employment payments), of which only the former is material in relation to the Group's consolidated financial statements.

As for the obligations assumed by Almirall Hermal GmbH, these benefits are structured into two defined benefit plans that were frozen in 2017, and a defined contribution plan with employer contributions:

- A defined contribution plan is a pension plan under which the Group pays fixed contributions to a fund and has no legal or constructive obligation to make additional contributions if the fund does not have sufficient assets to pay benefits related to services rendered in the current and prior fiscal years to all employees. Defined benefit plans, in contrast, establish the amount of benefits an employee will receive upon retirement, usually based on one or more factors, such as age, years of employment, and salary.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

- In the defined benefit plans, the contingencies covered are retirement, risks to active life, death and disability, for those employees with seniority starting prior to 30 June 2002, and the benefits consist of a pension determined, basically, by the pensionable salary. The assumed commitment is in an internal fund, with the corresponding provision, and there are no assets assigned to the plans (Note 20).

The liability recognised in the consolidated balance sheet in respect of the defined benefit pension plans is the present value of the defined benefit obligation as of the consolidated balance sheet date. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using the interest rates from high-quality corporate bonds expressed in the same currency in which the benefits will be paid, and whose terms to maturity are similar to those of the respective obligations. In countries where no market for this type of bonds has developed, the market rates for government bonds are used.

The amount of the commitments assumed has been determined by applying the following criteria:

- Method of calculation: the calculation method used in the actuarial valuations has been the "proportional crediting year by year" or "projected unit credit" method. The value of the pension obligations has been calculated based on the present value of the benefits agreed, taking into account the number of years that the member of staff has been employed and the years remaining until their retirement.
- Actuarial assumptions, which are detailed in Note 20.

Actuarial gains and losses arising from adjustments made based on experience and on changes in actuarial assumptions are charged or credited to consolidated equity in "Other comprehensive income" in the reporting period in which they arise.

Past service cost arises as a result of modifications to the benefits provided under a defined benefit plan. It may involve an improvement or a reduction in the benefits covered by the plan.

IAS 19 requires that past service cost be recorded directly in the consolidated income statement for the year in which the plan is modified. The entity recognises an expense when the change results in an improvement in benefits (increase of the past service cost), and it recognises income when benefits are reduced (reduction of the past service cost).

If new benefits are incorporated into a defined benefit plan, then this will have an immediate impact on the income statement, and it will not be possible to defer the expense that corresponds to those benefits that have not yet been accrued during the consolidation period.

The discount rates used in the calculation are established according to actuarial advice according to published statistics and experience in each territory.

In turn, the defined contribution plans provide coverage for contingencies similar to the defined benefit plans described above for all employees.

Once the contributions have been paid, the Group has no further payment obligations. Contributions are recognised as employee benefits when accrued.

n) Severance payments

Severance payments are made to employees as a result of the Group's decision to terminate their employment contract before the normal retirement age, or when the employee agrees to voluntarily resign in exchange for these benefits. The Group recognises these benefits when it has demonstrably committed to dismiss current employees in accordance with a detailed official plan that cannot be revoked. When an offer is made to encourage the voluntary resignation of multiple employees, severance payments are valued based on the number of employees expected to accept the offer.

o) Government subsidies

Government subsidies to cover current expenses are recognised in the consolidated income statement once all conditions have been met, and in the periods in which the related costs are offset, and they are deducted in the presentation of the relevant expense.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Government subsidies related to property, plant and equipment are treated as deferred income and are recorded in income over the course of the expected useful lives of the relevant assets.

p) Revenue recognition

The Group recognises as revenue the amount of the transaction price related to the consideration it expects to be entitled to receive for the transfer of goods to the customer, for services provided and other revenue in the ordinary course of business, which may consist of fixed or variable amounts or both. Revenue is presented net of returns, trade discounts, prompt payment discounts and contributions to health care systems (see Note 5-q) for further details).

The Group recognises revenue when it satisfies an obligation by transferring a good or service to the customer and the customer obtains control of the asset. The Group determines, at the inception of the contract, whether to satisfy the obligations over time or at a specific point in time, depending on the specific conditions for each of the Group's activities, as described below.

In accordance with IFRS 15, the Group takes into account the five-step model for determining when revenue and the amount thereof should be recognised, which consists in the following steps:

1. Identification of the contract with the customer.
2. Identification of the performance obligations contained in the contract.
3. Determination of the transaction price.
4. Allocation of the price between the various performance obligations.
5. Determination of the basis for revenue recognition, when a performance obligation is satisfied.

In this regard, for each performance obligation that is identified, the Group determines, at inception of the contract, whether it satisfies the performance obligation over time or at a specific point in time.

i) Sales of products

The Group's "product sales" are those derived from sales of proprietary medicinal products, active pharmaceutical ingredients and other non-prescription pharmaceutical products, where control is transferred to customers and service obligations are fulfilled when the goods are made available to customers, which in the Group's case are wholesalers, logistics operators, pharmacies and hospitals (in the various territories where the Group has a direct presence) or other pharmaceutical companies with which the Group has a distribution and/or licensing agreement for a specific territory and specific products.

In this regard, the Group distinguishes between three major segments in turnover (Note 24):

- Marketing through its own network: sale of proprietary medicinal products in territories where the Group has a direct presence (Europe and United States, as separated in the segmented information), i.e. it has a local sales network that makes medical visits to healthcare professionals (family doctors, specialists, etc.) or directly to retail channels (mainly pharmacies).
- Marketing through licensees: sale of proprietary medicinal products or active pharmaceutical ingredients to other pharmaceutical companies, which carry out the local promotional activity in those territories. These sales are linked to the licensing contracts described in section ii) of this Note.
- Third-party manufacturing and intermediation: sale of proprietary medicinal products where the Group provides a manufacturing service for a third party with little commercial risk (in general, the price is fixed at cost plus a mark-up) and where the main customer is Covis Pharma GmbH (hereinafter Covis), linked to the agreement explained in Note 12. This activity is reflected in the Corporate Services and Manufacturing segment.

IFRS 15 establishes that an entity that grants the right to return product must recognise revenue equal to the consideration to which it expects to be entitled in exchange for transferring the promised goods or services to a customer, as well as a refund liability and an asset for the right to recover the products. The Group recognises its revenue net of estimated returns at the date of sale, while at the same time recognising a refund liability. The Group does not recognise an asset for the right to recover goods because, based on experience and the type of marketed product, returned materials cannot be returned to the Group's inventory.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

The amount of recognised revenue is adjusted for expected returns, which are estimated based on the average return rate in recent years. Discounts granted to public customers are recorded as a deduction from revenue at the time the related revenue is recorded. Where appropriate, a liability is calculated on the basis of historical experience, which involves management judgements.

Therefore, the Group's revenue from product sales is subject to variable consideration for discounts, refunds and returns. This variable consideration is only recognised if it is highly probable that there will not be a material reversal in the amount of cumulative revenue recognised when the uncertainty associated with the variable consideration is subsequently resolved.

ii) Income from granting licenses

Mainly, although not exclusively, in countries where the Group does not have a direct presence, it grants other pharmaceutical companies licences to sell its products on an exclusive basis in a specific territory, furthermore undertaking to manufacture the pharmaceutical product for the customer in most cases. Sales for the supply of products are made on an arm's length basis and are recognised in accordance with paragraph (i) of this Note.

For these agreements, the Group generally charges an upfront payment for transfer of the licence, which is either non-refundable or may be refunded to the customer under strict conditions if the product is not finally authorised for distribution in the agreed territory. Given that these amounts are considered non-refundable in most cases, the revenue is recognised at the initial moment.

In addition, such contracts usually include additional payments linked to the assignment of intellectual property subject to the achievement of regulatory and/or commercial milestones, which are considered contingent until the corresponding milestone occurs (at which time revenue would be recognised), or royalties based on product performance (typically sales of product in the local market), which are recognised as such sales occur.

Finally, in certain cases the Group grants perpetual licences where the Group's obligations are minimal (beyond a transitional period until transfer of the commercial authorisation in the relevant territory or until effective transfer of the production site can take place). In these cases, the Group's obligations are deemed to be fulfilled at the time when the contract is signed, and all revenue is recognised at inception.

iii) Interest income

Interest income is recognised using the effective interest rate method. As a result of the Group's direct activity, it does not collect interest from its customers, rather only from the cash surpluses it places in financial instruments as mentioned in Notes 5-i) and 13.

q) Contributions to health systems

In the different territories where the Group operates, it is common that, in order to gain access to health system prescribers (health sector professionals such as family doctors or specialists) and, therefore, to be able to sell proprietary medicinal products through its network of coverage, it has to enter into agreements with governments (usually through the Ministry of Health) or private co-payment systems (mainly with insurance companies).

When accessing the national health system, in the case of proprietary medicinal products, the relevant commercial authorisation is required, as well as a reimbursement price, which is the price charged by the Group (although the patient pays a much lower price, the difference being borne by the State). For this reason, governments often have models of contributions to the national health system, which are paid by pharmaceutical companies based on the different products that are prescribed or administered in hospitals, either in the form of mandatory direct rebates or contributions according to the sales made on reimbursed products. This is the model found in most countries in Europe (with a welfare state model).

In other territories, such as the United States, prescriptions are channelled through private insurance companies, with which agreements are made to include the Group's products in their coverage plans, given that otherwise the patient would have to pay the full price of the proprietary medicinal product, and this would limit the commercial success of the product.

In both cases, the Group makes the best estimate of the costs associated with these contributions, which are recorded as a reduction in "Net turnover" in the consolidated income statement. The liability

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

is recorded under "Trade payables" (Note 19-a)) or "Provisions" (Note 21), depending on the expected time horizon for payment of the contributions.

r) Income tax, deferred tax assets and liabilities

The expense for Spanish corporate income tax and similar taxes applicable to foreign consolidated entities is recognised in the consolidated income statement, except when it results from a transaction the results of which are recorded directly in consolidated equity, in which case the related tax is also recorded in equity.

Almirall, S.A. is subject to Spanish Corporate Income Tax under the Spanish Tax Consolidation regime according to Chap. VI of Title VII of Law 27/2014, of 27 November, on Corporate Income Tax. The companies that are comprised in the Group for tax purposes for fiscal year 2023 are: Almirall, S.A., Laboratorios Almirall, S.L., Industrias Farmacéuticas Almirall, S.A., Laboratorios Tecnobío, S.A., Ranke Química, S.A., Almirall Europa Derma, S.A. and Almirall Holding Iberia, S.L.; for all of these, the first company mentioned acts as parent company. Consequently, the corporate income tax expense of the consolidated income statement includes the benefits derived from the application of tax loss and tax credit carryforwards that would not have been recorded if the companies comprising the tax group had been individually taxed.

Income tax represents the sum of the current income tax expense for the year and the change in recognised deferred tax assets and liabilities.

The income tax expense for the year is calculated based on the taxable income for the year. The taxable income differs from the net income presented in the consolidated income statement because it excludes items of income or expense that are taxable or deductible in other years and also excludes items that are never taxable or deductible. The Group's current tax liabilities (or assets) are calculated using tax rates that have been enacted or substantially enacted as of the consolidated balance sheet date. Management periodically evaluates the positions taken in tax returns in situations where the applicable tax regulation is subject to interpretation, and, if necessary, it establishes provisions based on the amounts that are expected to be paid to the tax authorities.

Deferred tax liabilities are the amounts of income tax payable in the future related to taxable timing differences, while deferred tax assets are the amounts of income tax recoverable due to the existence of deductible timing differences, tax loss carryforwards or deductions pending application. For these purposes, a timing difference is defined as the difference between the carrying value of assets and liabilities and their taxable base. These amounts are recorded by applying the tax rate at which they are expected to be recovered or settled to the relevant timing difference or credit. The Group recognises deferred tax liabilities in all cases except those arising from the initial recognition of goodwill or from an asset or liability in a transaction that is not a business combination, at the date of the transaction affecting neither accounting profit nor taxable profit or tax loss and at the date of the transaction no taxable and deductible temporary differences arise for the same amount and/or related to differences linked to investments in subsidiaries, affiliated companies and joint ventures over which the Group has the ability to control the timing of their reversal and it is not probable that they will reverse in the foreseeable future.

Current or deferred income tax is recognised in profit or loss, unless it arises from a transaction or economic event that is recognised in the same or a different period, against equity or from a business combination.

The Group recognises deferred tax assets whenever it is probable that sufficient future taxable profit will be available against which the deferred tax asset can be offset or when tax legislation provides for the possibility of the future conversion of deferred tax assets into a claim against the Tax Authorities or they correspond to temporary differences relating to investments in subsidiaries, affiliated companies and joint ventures to the extent that the temporary differences will reverse in the foreseeable future and it is expected that future taxable profit will be available against which the differences can be offset. However, assets arising from the initial recognition of assets or liabilities in a transaction that is not a business combination, which at the date of the transaction does not affect either accounting profit or taxable profit or tax loss and at the date of the transaction does not give rise to taxable and deductible temporary differences of the same amount arise, are not recognised.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

It is considered probable that the Group has sufficient taxable profit to recover deferred tax assets, provided that there are sufficient taxable temporary differences relating to the same taxable authority and referring to the same taxable person that are expected to reverse in the same tax year in which the deductible temporary differences are expected to reverse or in years in which a tax loss arising from a deductible temporary difference can be offset against earlier or later taxable profit. Where the only future taxable profits arise from the existence of taxable temporary differences, deferred tax assets arising from offsetting tax losses are limited to 70% of the amount of deferred tax liabilities recognised.

At the end of each accounting period, the deferred tax assets and liabilities recorded are reviewed in order to verify that they are still valid, and the appropriate adjustments are made in accordance with the results of the analyses conducted. The monetisation of deductions generated by research and development is considered in the analysis of the recovery of deferred tax assets.

Current or deferred income tax is recognised in profit or loss, unless it arises from a transaction or economic event that is recognised in the same or a different period, against equity or from a business combination.

Finally, in application of IFRIC 23 "Uncertainty over income tax treatment", the Group classifies liabilities arising from this rule under the heading of "Other non-current liabilities" (Note 19).

Offsetting and classification

The Group only offsets current income tax assets and liabilities if it has a legal claim against the tax authorities and it intends to either settle the resulting debts on a net basis or realise the assets and settle the debts simultaneously.

In the case of deferred income tax assets and liabilities, they are only offset if a legal right of offset exists vis-à-vis the tax authorities and those assets and liabilities relate to the same tax authority, and to the same taxable entity or to different taxable entities that intend to settle or realise the current tax assets and liabilities on a net basis, or realise the assets and settle the liabilities simultaneously, in each of the future periods in which significant amounts of deferred tax assets or liabilities are expected to be settled or recovered.

Deferred tax assets and liabilities are recognised in the consolidated balance sheet as non-current assets or liabilities, regardless of the expected date of realisation or settlement.

Monetisation

When the Group makes the decision to monetise tax credits, having certified reports that support these amounts and there is a reasonable estimate that the total average number of personnel or average R&D personnel will be maintained for two years, and it is reasonable to reinvest the amounts collected from the monetisation of these tax credits in R&D activities, the amount of the monetisation (80% of R&D tax credits) will be recognised as a deferred tax asset or as a tax loss carryforward, as appropriate.

Global minimum complementary tax

The Group's current income tax expense includes the tax related to the minimum effective taxation of multinational enterprise groups (OECD model rules (Pillar Two), hereinafter the Complementary Tax), provided that the subject Group company is a taxable person and the taxpayer. If the Group company subject to Complementary Tax is a substitute for a taxpayer that is not part of the Group, then the current income tax expense accrued on behalf of the taxpayer is recognised as a receivable from group companies.

If the Group company subject to Complementary Tax is a taxable person and taxpayer, but another company that is not part of the Group acts as a substitute for the company, the Group recognises the current accrued income tax expense with a credit to an account payable with group companies.

s) Interest cost

General and specific interest costs that can be attributed directly to the acquisition, construction or production of qualifying assets, which are those assets that necessarily require a substantial period of time before they are ready for their intended use or sale, are added to the cost of those assets until such time as the assets are substantially ready for their intended use or sale.

Other borrowing costs are recognised in income in the year in which they are incurred.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

t) Share-based remuneration systems

In 2008, the General Shareholders' Meeting ratified a long-term variable remuneration plan linked to the value of the Company's shares or Stock Equivalent Units Plan (hereinafter, the SEUS Plan) for the benefit of certain executives. Under the SEUS Plan, the Parent Company undertakes to grant the Executives a long-term variable remuneration linked to the value of the Parent Company's shares, provided that certain requirements and conditions are met. This variable remuneration is settled in cash in full.

On 10 May 2024, the General Meeting of Shareholders ratified a new long-term remuneration plan for Executives called the Performance Shares Plan (hereinafter, the PSP Plan), which came into effect in 2024 and replaces the SEUS Plan described above. The characteristics of this new plan are as follows:

- The PSP will be implemented in three-year cycles, starting on 1 January and ending on 31 December of the third year.
- The settlement will take place in March of the year following the end of the period, with 40% to be settled in cash and 60% to be settled in Almirall, S.A. shares.
- The valuation of this PSP plan is subject to the following objectives, with the relative weight indicated in parentheses: (i) Relative total return for the shareholder (35%), (ii) Accumulated EBITDA (35%), (iii) Employee satisfaction (7.5%), (iv) Reduction of the carbon footprint (7.5%) and (v) Progress in research and development (15%).

In accordance with IFRS 2, both the recognition and subsequent measurement of the PSP plan differ between the cash-settled and equity-settled portions.

The equity-settled portion is recognised as an expense in the consolidated income statement during the period of consolidation with a credit to equity (Note 16). The initial valuation is at fair value on the grant date, with no revaluation at subsequent closing dates.

The cash-settled portion is recognised as an expense in the consolidated profit and loss statement during the period of consolidation with a credit to liabilities (under Remuneration payable, Note 19). Both the initial valuation and subsequent valuations for each of the year-end periods for which the PSP plan is in effect are at fair value. In addition, a breakdown of the portion corresponding to the Board of Directors and to Senior Management can be found in Note 29.

u) Share capital

The subscribed capital is represented by ordinary shares.

Incremental costs directly attributable to the issuance of new shares, or a value reduction or the amortisation of existing shares, are presented in equity as a reduction, net of taxes, of the income earned.

When any Group entity acquires shares of the Parent Company (treasury shares), the consideration paid, including any directly attributable incremental cost (net of income tax) is deducted from the equity attributed to shareholders of the Company until the cancellation, reissue or disposal of the acquired treasury shares. When these shares are sold or subsequently reissued, any amount received, net of any directly attributable incremental transaction costs and the related income tax effects, are included in equity attributed to the shareholders of the Parent Company.

6. Changes in accounting policies

At the year ending on 31 December 2025, there have been no significant changes in the Group's accounting policies, nor have any new standards come into force that have an impact on the comparability of these consolidated financial statements with respect to those of the year ending on 31 December 2024.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

7. Critical accounting judgements and estimates

Estimates and judgements are evaluated on an ongoing basis and are based on historical experience and other factors, including expectations regarding future events that are believed to be reasonable under the circumstances.

a) Valuation of intangible assets - Licensing agreements with developments in progress

This section includes the Group's acquisitions of marketing rights for certain products that are in the development phase (Note 9), which meet the characteristics for initial recognition under IFRS (Note 5-b)).

The various payments arising from the contract are assessed at inception, and if they are contingent, they are not recognised until they are accrued (usually upon the achievement of a milestone).

Payments that occur upon the achievement of certain development, regulatory or commercial milestones (e.g. moving to a more advanced stage of development, obtaining regulatory approval or reaching a certain sales threshold), which confirm the increased value of the asset in question, are capitalised.

Conversely, when payments are linked to the performance of ordinary activities of the development stage that do not meet the condition for capitalisation (such as the performance of clinical trials or royalties on sales), they are recognised in the consolidated income statement when that are incurred.

These assets will be depreciated over the respective useful lives of the corresponding products starting from the moment when these products are commercially launched (after obtaining regulatory approval, if applicable). At the end of each accounting period, the Group is responsible for assessing the recoverability of these assets through the generation of positive cash flows in the future, pursuant to the best estimates of the Group's technical and financial managers. For this purpose, a business plan with a discounted cash flow is prepared which involves a degree of uncertainty inherent in consideration of the various possible scenarios. A variation of the assumptions made in the valuation of the expected cash flow (interest rate fluctuations, regulatory changes, final approval of the expected regulated prices, competition from other products, etc.) could reduce the realisable value of these assets (Note 9).

b) Impairment of goodwill and intangible assets

The determination of the potential goodwill impairment loss, as well as of any intangible assets with possible indications of impairment, requires the use of judgements and estimates regarding their recoverable value. These judgements and estimates rely mainly on the determination of the cash flows associated with the relevant cash-generating units, and on certain assumptions regarding the interest rates used in the discounted cash flows (Note 5-d) and 8). The use of other assumptions in the analysis of the recoverable value of goodwill and intangible assets could give rise to other considerations regarding the impairment thereof.

c) Deferred tax assets

In determining deferred tax assets for which the recoverability is deemed to be reasonably assured, the Group establishes a finite time frame for offsetting them, based on the best possible estimates. Accordingly, the expected application period for deferred tax assets has been determined using the estimate of the Group's taxable profits. Moreover, the legal deadlines for the use of these assets also takes into account the timetable for the use of deductions pending application, as well as the tax losses subject to offset in subsequent years (Note 23). Nevertheless, the Group has considered a maximum time frame of 10 years as a probable scenario for recoverability of these deferred tax assets, and hence it did not include in the recognition of the assets any tax credits that, according to the estimates of generation of future taxable profits, would require a longer period. Even though the tax legislation would allow inclusion of tax credits requiring more than 10 years for recovery, the Group does not consider the forecast beyond the 10-year time frame as a reliable scenario.

d) Provision for contingent liabilities (lawsuits, etc.)

The Group's activities fall within a highly regulated sector (health legislation, intellectual property, etc.), which increases its exposure to potential lawsuits arising from its activities.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

The claims and lawsuits to which the Group is subject are generally complex, meaning that their evolution can be highly uncertain, both as regards the probability of an outcome detrimental to the Group's interests, and as regards the estimate of potential future disbursements to be made by the Group. As a consequence, it is necessary to use judgements and estimates, counting on the support of the relevant legal consultants.

At the end of the fiscal years ending on 31 December 2025 and 2024, various legal proceedings and claims were initiated against the consolidated entities, arising from the ordinary course of their business. Both the Group's legal consultants and the Parent Company's Board of Directors believe that the conclusion of these proceedings and claims will not produce a significant effect on the consolidated financial statements for future fiscal years (Note 27).

8. Goodwill

The details of this heading of the consolidated balance sheet at year-end 2025 and 2024 is as follows (there have been no movements during 2025 and 2024):

	Thousands of Euros	
	31/12/2025	31/12/2024
Almirall, S.A.	35,407	35,407
Almirall Hermal GmbH	227,743	227,743
Poli Group	52,816	52,816
Total	315,966	315,966

The goodwill of Almirall, S.A., the net value of which amounts to €35.4 million, arose in 1997 from the difference between the value at which the shares of Prodesfarma, S.A. were recorded and the underlying book value of this company at the moment of the merger by absorption of this company by the Parent Company, once the unrealised gains arising from property, plant and equipment and financial assets had been assigned to the other assets. The remaining amount is the figure that remained to be amortised at the date of transition to IFRS on 1 January 2004, and the main products included already existed prior to the merger, mainly Almax and Ebastel, which are mainly sold in Spain and Europe, respectively. All associated intangible assets are fully amortised as at 31 December 2025 and 2024.

The goodwill of Almirall Hermal GmbH arose as a result of the difference between the acquisition value of the shares of the Hermal Group companies in 2007 and their theoretical value at the time of acquisition, after the difference between the fair value and the value at which they were recognised in the financial statements of the acquired companies had been assigned to the identifiable assets and liabilities, where applicable. The main products supporting this goodwill are those that were acquired, mainly in dermatology. The most prominent products are Decoderm and Balneum, which are mainly sold in Germany and other European countries. All associated intangible assets are fully amortised as at 31 December 2025 and 2024.

Poli Group's goodwill arose as a result of the difference between the acquisition value of the shares of Poli Group companies in February 2016 and their underlying value at the moment of acquisition, once the difference between their fair value and the value at which they were recorded in the financial statements of the acquired companies had been allocated to identifiable items of assets and liabilities. The main products supporting this goodwill are those that were acquired, mainly in dermatology, gynaecology and respiratory medicine. The most prominent products are Ciclopoli, which is sold worldwide (but mainly in Europe), and Finjuve, which is marketed through licensees in different territories around the world. Further details on the intangible assets linked to Poli Group's goodwill can be found in Note 9.

Impairment losses

At the end of the fiscal years ending on 31 December 2025 and 2024, the recoverable amount of all the goodwill was estimated based on calculations of value in use of the CGUs to which they are assigned, as described in Note 5-d).

As of 31 December 2025 and 2024, according to the estimates and projections available to the Parent Company's Board of Directors, the forecasts of results and discounted cash flows for the remaining

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

cash-generating units adequately support the carrying amounts of the related assets and, therefore, the related goodwill.

Goodwill	Asset or Cash Generating Unit	Thousands of Euros		Assumption 2025			Assumption 2024		
		Goodwill (*)	Intangible assets (*)	p.t.d.	a.t.d.	p.i.g.r.	p.t.d.	a.t.d.	p.i.g.r.
Almirall, S.A.	Assets present before the merger	35,407	-	12.2%	8.0%	(5)%	12.3%	8.0%	(5)%
Almirall Hermal GmbH	Assets from the takeover of Hermal GmbH	227,743	-	11.9%	8.0%	(2)%	12.0%	8.0%	(2)%
Poli Group	Assets from the takeover of Poli Group:								
	i) Licences and other commercialisation rights (product technology), own network segment	7,400	21,215	11.0%	8.0%	(2)%	11.0%	8.0%	(2)%
	ii) Licences and other commercialisation rights (product technology), third-party commercialisation segment	45,416	121,457	10.1%	8.0%	(1)%	10.3%	8.0%	(1)%
	iii) Acquired development costs (Terbinafine)	-	3,179	11.0%	8.0%	(2)%	11.3%	8.0%	(2)%
	iv) Acquired development expenses (Finjuve)	-	14,630	11.0%	8.0%	(2)%	10.9%	8.0%	(2)%
	Total	315,966	160,481						

p.t.d.: Pre-tax discount rate; p.t.d.: After-tax discount rate; a.t.d.: Perpetual income growth rate

Impairment tests assume flat or slightly declining sales, given that most of the portfolios are mature. The gross margin for impairment testing purposes is calculated on the basis of net turnover, net of Procurements and Royalties (which are recorded as Leases and royalties under the heading of Other operating expenses (Note 22)).

At 31 December 2025 and 2024, the sensitivity analysis performed due to reasonably possible variations in the main key assumptions (as described in Note 5-d) does not show any impact due to impairment according to the same variables that were used.

9. Intangible assets

The itemisation of the balance and changes of this heading in the accompanying consolidated balance sheets as of 31 December 2025 and 2024 is as follows:

Thousands of euros	Balance as at 31/12/2024	Recognitions	Transfers	Derecognitions	Translation differences	Balance as at 31/12/2025
Industrial property	2,193,420	56,440	-	(1,908)	(85,705)	2,162,247
Development costs ¹	111,378	28,078	-	-	(1,929)	137,527
Computer applications	93,942	4,755	4,028	(8,919)	(165)	93,641
Advances and property, plant and equipment in progress	67,840	14,221	(4,028)	-	-	78,033
Total cost Intangible Assets	2,466,580	103,494	-	(10,827)	(87,799)	2,471,448
A. Accum. Industrial property	(1,133,293)	(112,040)	-	1,721	38,502	(1,205,110)
A. Accum. Development costs	(3,243)	(2,527)	-	-	173	(5,597)
A. Accum. Computer applications	(73,950)	(8,593)	-	7,889	180	(74,474)
Total A. Accum. Intangible assets	(1,210,486)	(123,160)	-	9,610	38,855	(1,285,181)
Impairment losses	(319,127)	-	-	1,010	26,182	(291,935)
Net Value Intangible assets	936,967	(19,666)	-	(207)	(22,762)	894,332

¹ Additions to the Development expenses heading include €28,078 thousand of internally generated expenses in the fiscal year ending at 31 December 2025.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Thousands of euros	Balance as at 31/12/2023	Recognitions	Transfers	Derecognitions	Translation differences	Balance as at 31/12/2024
Industrial property	2,102,789	54,712	38	(8,323)	44,204	2,193,420
Development costs ¹	87,997	20,354	-	-	3,027	111,378
Computer applications	103,326	5,201	4,969	(19,642)	88	93,942
Advances and property, plant and equipment in progress	55,049	19,511	(5,007)	(1,713)	-	67,840
Total cost Intangible Assets	2,349,161	99,778	-	(29,678)	47,319	2,466,580
A. Accum. Industrial property	(1,013,911)	(105,771)	-	6,561	(20,172)	(1,133,293)
A. Accum. Development costs	(2,246)	(962)	-	-	(35)	(3,243)
A. Accum. Computer applications	(85,663)	(7,703)	-	19,490	(74)	(73,950)
Total A. Accum. Intangible assets	(1,101,820)	(114,436)	-	26,051	(20,281)	(1,210,486)
Impairment losses	(295,926)	(31,242)	-	21,344	(13,303)	(319,127)
Net Value Intangible assets	951,415	(45,900)	-	17,717	13,735	936,967

¹ Additions to the Development expenses heading include €20,354 thousand of internally generated expenses in the fiscal year ending at 31 December 2024.

The intangible assets described in the table above have finite useful lives, and the majority of them have been acquired from third parties or as part of a business combination, with the exception of the internally generated development costs described further below in this Note. There are no assets subject to debt guarantees.

During 2025, the main additions of intangible assets amounted to €103.5 million, which correspond to:

- In February 2025, the first development milestone accrued in the amount of €5.8 million, linked to the exclusive licence agreement for ISB 880, the IL-1RAP antagonist with Ichnos Science.
- In October 2025, the first sales milestone of the Ebglyss contract with Lilly accrued, amounting to \$6 million (equivalent to €5.2 million).
- In December 2025, the fifth sales milestone of the Ilumetri contract with Sun Pharma accrued, amounting to \$55 million (equivalent to €46.8 million). It is outstanding as at 31 December 2025 (Note 19-b)).
- During the year, some development milestones of ongoing development projects with Evotec, Epimab and Absci were met, and a new agreement was signed with Simcere for two new candidates. In total, milestones worth €5.8 million have been accrued.
- Following the EMA's approval of Ebglyss in November 2023 (indicated for atopic dermatitis), certain clinical studies related to this product began to be capitalised. The total amount capitalised for internally generated expenses in 2025 amounts to €28.1 million.

During the 2024 fiscal year, the main additions of intangible assets amounted to €99.8 million and corresponded to:

- In February 2024, a development and licensing agreement was signed with Novo Nordisk for the rights to NN-8828 for the use thereof in various fields, including immune-mediated inflammatory skin diseases. NN-8828 is an IL-21 blocker that inhibits IL-21-induced pathophysiological functions in several immunomodulatory diseases. Under the terms of this agreement, an initial payment of €10 million has been made.
- In March 2024, an agreement was signed with Eloxx Pharmaceuticals Inc. for the rights to ZKN-013, including its use in orphan dermatological diseases. ZKN-013 is a potentially promising oral drug for reading nonsense mutations, which allows host cells to produce functional proteins that counteract the root cause of these rare dermatological diseases and potentially others. Under the terms of this agreement, the Group has accrued \$5.4 million (equivalent to €5.0 million), of which \$2.4 million were outstanding as at 31 December 2024, having been paid in January 2025 (Note 19-b).
- In July 2024, an addendum to the contract with Athenex was signed, amending certain terms of the original contract signed in 2017. As a result of this addendum, \$8.3 million (equivalent to

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

€7.6 million) were paid for acquisition of the worldwide rights to the product marketed under the Klisyri trademark.

- In November 2024, the fifth sales milestone of the Ilumetri contract with Sun Pharma accrued, amounting to \$45 million (equivalent to €43.3 million). It was pending payment as of 31 December 2024 (Note 19-b), having been paid in April 2025.
- In December 2024, the second sales milestone related to the licensing agreement with MC2 Therapeutics accrued (under which the product Wynnzora is marketed), in the amount of €4 million. It was pending payment as of 31 December 2024 (Note 19-b), having been paid in January 2025).
- Following the EMA's approval of Ebglyss in November 2023 (indicated for atopic dermatitis), certain clinical studies related to this product began to be capitalised. The total amount capitalised in 2024 amounted to €20.4 million.

The write-offs for the 2025 financial year are mainly due to obsolete software (replaced by new applications) that was fully amortised, as well as patents corresponding to discontinued projects during the year. These disposals have resulted in a loss of €0.2 million, which has been recorded under "Net gains (losses) on disposal of assets" in the consolidated income statement for the year ended 31 December 2025 (Note 22).

Disposals for the 2024 financial year were due to termination of the contract with Isolex, which resulted in the write-off of the initial payment made in 2023 (€1.7 million), and were due to the discontinuation of one of the products that came from the takeover of Aqua Pharmaceuticals (Altabax), whose net book value amounted to €0.7 million. Both disposals represented a loss of €2.4 million, which was recorded under "Net gains (losses) on disposal of assets" in the consolidated income statement for the year ended 31 December 2024 (Note 22). Additionally, in 2024, computer software that was no longer in use and the net book value of which was zero was derecognised, wherefore it had no impact on the consolidated income statement for the year.

The transfers for 2025 and 2024 are mainly related to software that has been put into operation during those years.

The translation differences for fiscal years 2025 and 2024 are mainly due to the evolution of the US dollar's exchange rate, mainly linked to the portfolio of 5 speciality products for the treatment of acne, psoriasis and dermatosis, which were acquired in 2018 from Allergan Sales, LLC and Allergan Pharmaceuticals International Limited ("Allergan").

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

The itemisation of the main assets included under the intangible assets heading is as follows, by carrying amount:

(Thousands of Euros)	Year of acquisition	Main products	Carrying amount 31/12/2025	Carrying amount 31/12/2024	Initial useful life (years)	Remaining useful life (31/12/25)
a) Assets from the takeover of Poli Group:						
i) Licences and other commercialisation rights (product technology)	2016	Ciclopoli	142,672	163,401	14-18	7-11
ii) Acquired development costs	2016	Finjuve	17,809	19,842	10-15	6-11
b) Rights acquired from Sun Pharma for Europe	2016	Ilumetri	168,024	137,453	15	8
c) Rights acquired from AstraZeneca for Spain	2017	Crestor and Provisacor	16,772	25,158	10	2
d) Rights acquired from Athenex for the United States and Europe	2017	Klisyri	48,471	60,835	10	6
e) Rights acquired from Allergan for the United States	2018	Seysara and Cordran Tape	112,284	146,183	5-15	0-8
f) Rights acquired from Lilly for Europe	2019	Ebglyss	147,387	160,068	10	8
g) Rights acquired from MC2 Therapeutics for Europe	2021	Wynzora	13,869	16,180	10	6
h) Rights acquired from Ichnos for the whole world	2021	Anti-IL-1RAP mAb	26,600	20,800	In progress	In progress
i) Development technology and rights acquired from Evotec for the whole world	2022	N/A	2,700	2,900	5	1.5
j) Rights acquired from Simcere for the whole world (except China)	2022	IL-2muFc	20,357	18,129	In progress	In progress
k) Renewal of rights acquired from MSD for Spain	2023	Efficib and Tesavel	-	6,000	3	-
l) Rights acquired from DFT El Globo S.L. for Europe	2023	Physiorelax	8,783	10,023	10	7
m) Rights acquired from Novartis AG for Spain	2023	Prometax	40,407	45,677	10	8
n) Intellectual property and development technology acquired from Etherna for the whole world	2023	N/A	11,120	13,741	Ongoing / 3	N/A / 1
o) Rights acquired from Novo Nordisk for Europe	2024	anti-IL-21 mAb	10,000	10,000	In progress	N/A
p) Rights acquired from Eloxx Pharmaceuticals for the whole world	2024	ZKN-013	5,038	5,038	In progress	N/A
Costs for developments made by the company	N/A		72,092	49,047	10/ In progress	7 / N/A
Other intangible assets	N/A		29,947	26,492		
Total intangible assets			894,332	936,967		

The main assets included under this heading as at 31 December 2025 are detailed below:

- a) Intangible assets acquired from Poli Group in 2016 (as detailed in Note 8) for an initial amount of €428.4 million corresponding mainly to product technology (€348.2 million) and development costs (€80.2 million).
- b) Marketing rights for Europe for a product for the treatment of psoriasis, under the trade name Ilumetri, arising from the agreement signed in 2016 with Sun Pharma, which includes additional payments for achieving sales milestones amounting to 70 million dollars.
- c) Marketing rights for Spain arising from the agreement with AstraZeneca signed in 2017 for two products for the treatment of hypertension marketed under the trade name Of Crestor and Provisacor, for an initial amount of €83.9 million.
- d) Marketing rights for Europe and the United States from the agreement with Athenex, for a product to treat actinic keratosis under the Klisyri trademark. These rights stem from the agreement signed in 2017 with Athenex, which provides for sales milestone payments of up to \$330 million.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

- e) Portfolio of 5 speciality products for the treatment of acne, psoriasis and dermatosis, which were acquired from Allergan Sales, LLC and Allergan Pharmaceuticals International Limited ("Allergan") on 21 September 2018 for €471.2 million (equivalent to US\$548 million), corresponding to the trademarks, intellectual property, regulatory approval documents, and the licenses for being the exclusive distributor of the dermatological products in the United States.
- f) Development and marketing rights for Europe for the product for treating atopic dermatitis (Lebrikizumab, marketed under the Ebglyss trademark), which was approved by the EMA on 17 November 2023 and launched in December 2023. These rights stem from the agreement signed in 2019 with Dermira (subsequently acquired by Lilly), under which the Group is obligated to make additional payments of up to \$119 million upon reaching certain net sales thresholds in Europe.
- g) Marketing rights for Europe for the product for treating psoriasis, marketed under the Wynzora trademark, commercially launched in 2022. These rights stem from the agreement signed in 2021 with MC2 Therapeutics, which contemplates payments for sales milestones (up to a maximum of €221 million).
- h) Worldwide development and marketing rights derived from the agreement signed in 2021 with Ichnos Science for ISB 880, an IL-1RAP antagonist monoclonal antibody for use in autoimmune diseases (Anti-IL-1RAP mAb). The contract provides for additional payments for marketing and development milestones (up to a maximum of €219 million) and for sales milestones (up to a maximum of \$400 million).
- i) Rights related to the research and development agreement with Evotec International GmbH. This agreement was signed in 2022, and the Group may make research and milestone payments of up to €230 million per programme.
- j) Exclusive licence rights worldwide except for the China region (mainland China, Hong Kong, Macau and Taiwan) for SIM0278, the IL-2 mutant fusion protein (IL-2Mu-Fc) developed by Simcere and drug candidate for the treatment of autoimmune diseases. That agreement was signed in 2022 and the Group may pay out up to \$488 million in development and commercial milestone payments based on achievements in various indications, with a significant portion as sales milestones.
- k) Rights acquired from MSD for Spain for the products marketed under the Efficib and Tesavel trademarks, for an additional period of 3 years (until 31 December 2025). This contract has been extended for an additional period of 2 years (until 31 December 2027) with no additional payment.
- l) Rights acquired from DFT El Globo S.L. in 2023 corresponding to various products marketed in Spain under the Physiorelax trademark.
- m) Rights acquired from Novartis AG in 2023 for Prometax® in Spain, a product for treating Alzheimer's disease. The agreement provides for an additional payment of €10 million, recorded under "Other non-current liabilities" (Note 19-b)), linked to the fulfilment of a regulatory milestone that is expected to be resolved by 31 December 2028.
- n) Rights acquired from Ethernal in 2023 for research and development of mRNA-based therapies in medical dermatology, as well as access to Ethernal's technology platform. The agreement provides for additional payments of 300 million euros, linked to the achievement of certain development and commercial milestones.
- o) Rights to NN-8828 acquired from Novo Nordisk in 2024 for use in various fields, including immune-mediated inflammatory skin diseases. NN-8828 is an IL-21 blocker that inhibits IL-21-induced pathophysiological functions in several immunomodulatory diseases. The agreement provides for additional payments for various development milestones (up to a maximum of €140 million) and milestones for reaching certain sales thresholds.
- p) Rights to ZKN-013 acquired from Eloxx Pharmaceuticals Inc. in 2024, including for use in orphan dermatological diseases. ZKN-013 is a potentially promising oral drug for reading nonsense mutations, which allows host cells to produce functional proteins that counteract the root cause of these rare dermatological diseases and potentially others. The agreement

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

includes additional payments for various development and marketing milestones and for reaching certain sales thresholds, up to a maximum amount of \$464 million.

Impairment losses

The Group has conducted the impairment analyses for those intangible assets, both those in progress and those showing indications of impairment. The key assumptions used for the impairment analyses, as well as the related sensitivity analyses, are shown further below in this Note.

The itemisation and changes of impairment losses on intangible assets recorded during 2025 and 2024 are as follows:

	Thousands of Euros								
	Balance as at 31/12/2023	Additions	Derecognitions	Translation differences	Balance as at 31/12/2024	Additions	Derecognitions	Translation differences	Balance as at 31/12/2025
Industrial property	245,298	31,242	(21,344)	13,303	268,499	-	-	(26,182)	242,317
Development costs	49,031	-	-	-	49,031	-	-	-	49,031
Computer applications	1,597	-	-	-	1,597	-	(1,010)	-	587
Total impairment losses	295,926	31,242	(21,344)	13,303	319,127	-	(1,010)	(26,182)	291,935

At the end of the 2025 financial year, the Group's Management has reassessed the business plans for the products marketed under the Seysara and Cordran Tape brands, with no significant difference detected between the value in use and their carrying amount. Additionally, the business plans for the various early-stage development projects have been evaluated, in all cases resulting in values exceeding the carrying amount. Therefore, no amount has been recorded in the item "Result from impairment of tangible fixed assets, intangible assets and goodwill" in the consolidated income statement for the year ended 31 December 2025.

At year-end 2024, the Group's Management reassessed the business plan for the products marketed under the Seysara and Cordran Tape brand, which form a part of the Allergan CGU portfolio.

- In the case of Seysara, its performance improved in 2024, and additionally, agreements were signed to distribute this product in new countries such as Canada and Mexico through the licensee segment. As a result, the business plan improved, mainly due to a higher level of revenues, therefore recording a partial reversal of the impairments made in previous years amounting to €21.3 million (equivalent to \$22.9 million).
- In the case of Cordran Tape, the product had experienced a progressive reduction in sales in recent years. Additionally, in 2025, as a result of the change of manufacturer for the product, a certain temporary supply shortage was expected, which was going to negatively impact the product's sales level in the medium term (which indeed occurred in the first quarter of 2025). As a consequence, the new business plan drawn up by the Group's Management resulted in an impairment of €31.2 million (equivalent to \$33.8 million).

There are no significant derecognitions in 2025. The derecognitions in 2024 corresponded to the partial reversal of the impairment made in previous years on Seysara (Allergan CGU portfolio), as described above.

Generated or reversed impairment losses have been recorded under "Impairment losses on property, plant and equipment, intangible assets and goodwill" in the accompanying consolidated income statements for 2025 and 2024.

As of 31 December 2025 and 2024, the accumulated impairment amount under the Intangible Assets heading corresponds mainly to:

- Impairment of the "Allergan portfolio", corresponding to the Seysara and Cordran Tape products, for a total of €123.1 million (€139.1 million in 2024), as described in the same Note.
- Impairment of technology acquired from Almirall LLC (formerly Aqua Pharmaceuticals, LLC) in 2013, allocated to each product and defined as a pool of intangible assets totalling €76.9 million in 2025 (€86.9 million in 2024).

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

- Impairment of acquired development costs as a result of the takeover of Polichem Group following the decision to cease development activities on two projects in the United States and one in Europe: P 3058 (Onychomycosis) in the amount of €7 million and P 3073 (Nail Psoriasis) in the amount of €45.7 million.
- Impairment of €12 million on marketing rights for various dermatological products acquired from Shire in 2007.

The main assumptions of the impairment tests performed on assets that do not form part of a CGU associated with goodwill (Note 8), on assets that are not yet amortised because they are in progress or on assets for which there are indications of impairment at 31 December 2024 are set out below:

Asset or Cash Generating Unit	Thousands of euros	Assumption 2025			Assumption 2024			
		Intangible assets	p.t.d.	a.t.d.	p.i.g.r.	p.t.d.	a.t.d.	p.i.g.r.
Rights acquired from Allergan for the United States	112,284		9.3%	8.5%	(15)%	10.5%	8.5%	(15)%
Rights acquired from Ichnos for the whole world	26,600		11.1%	9.0%	(15)%	11.0%	9.0%	(15)%
Rights acquired from Simcere for the whole world (except China)	20,357		11.2%	9.0%	(15)%	10.9%	9.0%	(15)%
Intellectual property and development technology acquired from Etherna for the whole world	11,120		10.9%	9.0%	(15)%	-	-	-
Rights acquired from Novo Nordisk for Europe	10,000		11.0%	9.0%	(15)%	-	-	-
Rights acquired from Elox Pharmaceuticals for the whole world	5,038		11.1%	9.0%	(15)%	-	-	-

p.t.d.: Pre-tax discount rate; p.t.d.: After-tax discount rate; a.t.d.: Perpetual income growth rate

In addition, we provide a sensitivity analysis performed on the most significant assets and CGUs that present changes in their carrying value at 31 December 2025 due to reasonably possible variations in key assumptions (as described in Note 5-d)). For the other unitemised assets and CGUs, there is no impact due to impairment according to the same variables used:

Cash-Generating Unit	Sensitivity analysis	Impact on value (millions of euros)
Rights acquired from Allergan for the United States	- Increase / Reduction of estimated net sales by 10%	+25 / (26)
	- Increase / Reduction of five points in the growth rate.	+1 / (5)
	- Increase / Reduction of 0.5% in the discount rate	(4) / +5

10. Right-of-use assets

This heading includes assets corresponding to leasing contracts, which mainly reflect the leasing of offices and transportation equipment (Note 5-e)). The breakdown of the balance and the consolidated movements as of 31 December 2025 and 2024 has been as follows:

Thousands of euros	Balance as at 31/12/2024	Recognitions	Derecognitions	Translation differences	Balance as at 31/12/2025
Construction	59,341	943	(697)	(195)	59,392
Machinery	41	-	(13)	-	28
Transport equipment	10,008	5,464	(4,224)	(72)	11,176
Total cost Rights of use	69,390	6,407	(4,934)	(267)	70,596
A. Accum. Construction	(21,331)	(5,359)	697	(190)	(26,183)
A. Accum. Machinery	49	(62)	13	-	-
A. Accum. Transport equipment	(4,522)	(3,323)	4,224	(16)	(3,637)
Total A. Accum. Rights of use	(25,804)	(8,744)	4,934	(206)	(29,820)
Net Value Rights of use	43,586	(2,337)	-	(473)	40,776

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Thousands of euros	Balance as at 31/12/2023	Recognitions	Derecognitions	Translation differences	Balance as at 31/12/2024
Construction	56,820	5,168	(2,821)	174	59,341
Machinery	137	-	(96)	-	41
Transport equipment	9,976	3,005	(2,973)	-	10,008
Total cost Rights of use	66,933	8,173	(5,890)	174	69,390
A. Accum. Construction	(19,117)	(4,960)	2,821	(75)	(21,331)
A. Accum. Machinery	(43)	(4)	96	-	49
A. Accum. Transport equipment	(4,757)	(2,738)	2,973	-	(4,522)
Total A. Accum. Rights of use	(23,917)	(7,702)	5,890	(75)	(25,804)
Net Value Rights of use	43,016	471	-	99	43,586

The additions for the year 2025 mainly relate to the renewal of vehicle fleets of the sales networks in Spain and Germany. The additions for the 2024 financial year corresponded mainly to the signing of a new contract for the offices of the subsidiary Almirall SaS (France) for a period of 9 years.

The main asset refers to the lease agreement of the Group's headquarters, with a net carrying amount of €22.8 million at 31 December 2025 (€26.1 million at 31 December 2024). The Group's head office is leased to the related entity Sinkasen S.L.U. (Note 28), under a contract that was renewed in January 2023 for a period of ten years (until 31 December 2032). There are no other contracts that are individually relevant.

The payments made in financial years 2025 and 2024 for leases amounted to €9,518 thousand and €8,582 thousand, respectively.

The itemisation of lease liabilities as of 31 December 2025 and 2024 is as follows, together with their future maturities (which coincide with the minimum future payments):

Thousands of euros	Balance as at 31/12/2025	Balance as at 31/12/2024
Liabilities for leasing		
Non-current	34,508	37,521
Current	7,775	7,061
Total	42,283	44,582

Liabilities for leasing	Maturities	Thousands of Euros
Current	Up to 6 months	3,938
	From 6 months to 1 year	3,837
Non-current	From 1 to 2 years	7,478
	From 2 to 3 years	7,096
	From 3 to 4 years	5,270
	From 4 to 5 years	4,898
	More than 5 years	9,766
Total		42,283

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

11. Property, plant and equipment

The changes under this heading in the consolidated balance sheets for 2025 and 2024 were as follows:

Thousands of euros	Balance as at 31/12/2024	Recognitions	Transfers	Derecognitions	Translation differences	Balance as at 31/12/2025
Land and construction	102,746	1,077	6,737	-	-	110,560
Technical installations and machinery	104,935	3,095	12,061	(3,319)	(282)	116,490
Other facilities, tools and furnishings	254,826	12,857	11,823	(22,988)	(219)	256,299
Other property, plant and equipment	14,446	2,281	1,228	(1,955)	(135)	15,865
Advances and property, plant and equipment in progress	30,912	15,690	(31,849)	(5)	(317)	14,431
Total cost Property, plant and equipment	507,865	35,000	-	(28,267)	(953)	513,645
A. Accum. Land and construction	(56,096)	(2,623)	-	-	-	(58,719)
A. Accum. Technical installations and machinery	(68,061)	(4,630)	-	3,319	78	(69,294)
A. Accum. Other facilities, tools and furnishings	(219,859)	(9,899)	-	22,985	224	(206,549)
A. Accum. Other property, plant and equipment	(10,059)	(2,127)	-	1,932	35	(10,219)
Total A. Accum. Property, plant and equipment	(354,075)	(19,279)	-	28,236	337	(344,781)
Impairment losses	-	-	-	-	-	-
Net value Property, plant and equipment	153,790	15,721	-	(31)	(616)	168,864

Thousands of euros	Balance as at 31/12/2023	Recognitions	Transfers	Derecognitions	Translation differences	Balance as at 31/12/2024
Land and construction	96,287	1,019	7,264	(1,826)	2	102,746
Technical installations and machinery	102,954	1,874	1,887	(1,815)	35	104,935
Other facilities, tools and furnishings	252,333	7,300	10,247	(15,153)	99	254,826
Other property, plant and equipment	20,066	1,660	609	(7,913)	24	14,446
Advances and property, plant and equipment in progress	32,661	17,982	(20,007)	(7)	283	30,912
Total cost Property, plant and equipment	504,301	29,835	-	(26,714)	443	507,865
A. Accum. Land and construction	(53,779)	(2,315)	-	-	(2)	(56,096)
A. Accum. Technical installations and machinery	(65,830)	(3,994)	-	1,771	(8)	(68,061)
A. Accum. Other facilities, tools and furnishings	(226,551)	(8,852)	-	15,601	(57)	(219,859)
A. Accum. Other property, plant and equipment	(16,854)	(1,785)	-	8,592	(12)	(10,059)
Total A. Accum. Property, plant and equipment	(363,014)	(16,946)	-	25,964	(79)	(354,075)
Impairment losses	-	-	-	-	-	-
Net value Property, plant and equipment	141,287	12,889	-	(750)	364	153,790

The additions for financial year 2025 are mainly due to upgrades at the production centres of the Group's pharmaceutical plants and improvements at the Group's headquarters and in the R&D centre. The additions for the 2024 financial year were mainly due to upgrades at the production centres of the Group's pharmaceutical plants and improvements at the Group's headquarters and in the R&D centre.

The transfer of property, plant and equipment in progress, carried out by the Group in the fiscal years ending on 31 December 2025 and 2024, corresponds basically to the transfer of investment projects at the production centres that began operations during those years.

During 2025 and 2024, several assets that were fully depreciated and in disuse, mainly consisting of production centres located in Spain, were written off.

In October 2025, a mutual exclusivity letter was signed with a buyer interested in one of the buildings that are part of the industrial complex owned by the Group in Reinbek (Germany). Since then, the process has progressed favourably, and the parties expect to close the sale in the first quarter of 2026. The negotiated sale price is €3.2 million, with an estimated net gain of approximately €1.4 million, which

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

will be recorded in the consolidated income statement for the 2026 financial year. This divestment does not affect any operating assets.

The main properties owned by the Group, as well as the subsidiary to which they belong, the country where they are located and the net book value (also including machinery, laboratory equipment and other items at these locations) at the end of 2025 and 2024 are detailed below (in thousands of euros):

Type of property	Country	Subsidiary	Carrying amount 31/12/2025	Carrying amount 31/12/2024
Chemical plants	Spain	Ranke Química, S.A.	14,572	12,097
Pharmaceutical plant	Spain	Industrias Farmacéuticas Almirall, S.A.	53,797	46,493
Pharmaceutical plant	Germany	Almirall Hermal GmbH	44,753	42,406
R&D Center	Spain	Almirall, S.A.	32,116	28,291

Details of the criteria according to which these assets are assessed for indications of impairment can be found in Note 5-d). As of 31 December 2025 and 2024, the Group does not hold any non-impaired assets that are not used in operations.

The Group occupies various facilities under operating leases, as indicated in Note 10.

The Group has taken out insurance policies to cover the possible risks to which the various items of its property, plant and equipment are subject, as well as the possible claims that may arise in the course of its operations, and it considers that these policies sufficiently cover the risks to which these items are subject.

No property, plant and equipment is subject to any mortgage guarantee.

12. Non-current financial assets/current financial assets/cash equivalents and other current assets

As explained in Note 5-j) and pursuant to IFRS 9, the Group classifies its financial assets into the following measurement categories:

- those subsequently measured at fair value (either through other comprehensive income or through profit or loss), and
- those that are measured at amortised cost.

Thus, this classification is distributed as follows:

- Financial assets measured at fair value through profit or loss: these assets do not meet the criteria for classification at amortised cost in accordance with IFRS 9 because their cash flows do not only represent payments of principal and interest. Consequently, this heading includes not only the balances receivable arising from recognition of the sale of the respiratory business in 2014, as explained below in this Note (agreement with Covis), but also the derivative financial instruments that do not qualify for hedge accounting.
- Financial assets measured at fair value through other comprehensive income: this heading includes equity instruments over which the Group does not have control, wherefore they are not included within the scope of consolidation. As of 31 December 2025 and 2024, there are no such instruments.
- Financial assets valued at amortised cost: this heading includes fixed-income investments made through deposits with maturities of less than one year, mainly in euros, although they may occasionally be in foreign currencies in the event of a surplus (normally dollars). At the date of initial application, the Group's business model is to hold these investments in order to receive contractual cash flows that only represent payments of principal and interest on the principal amount.

Non-current financial investments

The composition and changes under this heading in the consolidated balance sheet in 2025 and 2024 were as follows:

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Thousands of euros	Balance as at 31/12/2024	Recognitions	Changes in fair value	Transfers	Derecognitions	Translation differences	Balance as at 31/12/2025
Fair value through profit or loss	14,698	-	-	(2,120)	-	-	12,578
Fair value, changes in equity	-	-	-	-	-	-	-
Amortised cost	1,652	8,552	-	-	(15)	(77)	10,112
Total cost	16,350	8,552	-	(2,120)	(15)	(77)	22,690
Fair value through profit or loss	-	-	-	-	-	-	-
Fair value, changes in equity	-	-	-	-	-	-	-
Amortised cost	-	-	-	-	-	-	-
Total impairment	-	-	-	-	-	-	-
Net Value	16,350	8,552	-	(2,120)	(15)	(77)	22,690

Thousands of euros	Balance as at 31/12/2023	Recognitions	Changes in fair value	Transfers	Derecognitions	Translation differences	Balance as at 31/12/2024
Fair value through profit or loss	20,893	-	2	(6,197)	-	-	14,698
Fair value, changes in equity	-	-	-	-	-	-	-
Amortised cost	8,602	237	-	-	(7,365)	178	1,652
Total cost	29,495	237	2	(6,197)	(7,365)	178	16,350
Fair value through profit or loss	-	-	-	-	-	-	-
Fair value, changes in equity	-	-	-	-	-	-	-
Amortised cost	(6,617)	-	-	-	6,763	(146)	-
Total impairment	(6,617)	-	-	-	6,763	(146)	-
Net Value	22,878	237	2	(6,197)	(602)	32	16,350

Assets at fair value through profit or loss

Assets at fair value through profit or loss consist entirely of the financial asset linked to the agreement with Covis. This asset originated in November 2014 when the Group transferred to AstraZeneca the rights to part of its respiratory franchise (Eklira and Duaklir, and other brands with the compound acclidinium bromide), which included several components that involved receiving cash and deferred payments based on certain future milestones. On 5 January 2022, the agreement between AstraZeneca and Covis for the transfer of these rights entered into force. At 31 December 2025, the remaining amount receivable consists entirely of the net present value of royalties receivable from 2027 onwards. The royalties receivable in 2026 are classified under the heading "Trade and other receivables" (Note 15).

The fair value of this transaction was determined upon initial recognition by an independent expert. The method used consisted in discounted cash flows adjusted for the probability of success of certain risks associated with the different phases of the products. Using this method, the future cash flows generated by the asset are estimated (converted from US dollars to euros at the exchange rate according to the range of dates stipulated in the agreement) for the estimated marketing period, taking into account the expiration of the patent. These cash flows are discounted at a rate that reflects the current required rate of return on the market and the specific risks of the asset. Changes in the fair value of this financial asset are recorded under the heading "Other income" in the consolidated income statement (Note 22).

The main assumptions and considerations applied in the valuation of financial assets as of 31 December 2025 are as follows:

- Level of revenue reached in future years derived from the contract with Covis.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

- Discount rate: depending on the countries where the cash flows will be obtained by Covis, resulting in an overall weighted average of approximately 10.2%.

The changes of these assets in the consolidated balance sheet and the cash flows that have occurred, as shown in detail in the Consolidated Cash Flow Statement, are detailed below:

Thousands of euros	Balance as at 31/12/2024	Changes in fair value	Transfers	Cash Flow	Balance as at 31/12/2025
Non-current financial assets (Note 12)	14,698	-	(2,120)	-	12,578
Trade and other receivables (Note 15)	6,243	-	2,120	(5,662)	2,701
Total	20,941	-	-	(5,662)	15,279

Thousands of euros	Balance as at 31/12/2023	Changes in fair value	Transfers	Cash Flow	Balance as at 31/12/2024
Non-current financial assets (Note 12)	20,893	2	(6,197)	-	14,698
Trade and other receivables (Note 15)	13,198	-	6,197	(13,152)	6,243
Total	34,091	2	-	(13,152)	20,941

The cash flows for the 2025 and 2024 financial years correspond entirely to royalties.

Assets at amortised cost

The assets at amortised cost mainly consist of long-term deposits and the long-term receivable linked to the agreement signed in 2025 with Gedeon explained in Note 17 (which accounts for the bulk of the additions in 2025). As at 31 December 2023, there were loans to the company to which the subsidiary ThermiGen LLC was sold in 2021. (Celling Aesthetics LLC and other related companies), which were fully impaired. At the end of 2024, an agreement was reached with this company to settle the outstanding debt, whereby \$0.5 million (equivalent to €0.5 million) were collected. As a result, this debt was derecognised and the positive impact of its collection was recorded under other financial income in the consolidated income statement (Note 22).

Current financial investments

At 31 December 2025, this heading mainly includes accrued interest receivable and short-term guarantees. In the case of short-term investments that do not meet the criteria to be considered cash equivalents (Note 13), they are classified under this heading. Investments made during 2025 earned an average interest rate of 2.4% (3.6% in 2024).

13. Cash and cash equivalents

Cash and cash equivalents include cash on hand, demand deposits with banks and other short-term, highly liquid investments with an original maturity of three months or less, as explained in Note 5-i), otherwise they are considered current financial investments).

Part of the bank accounts are interest-bearing, with an average accrued interest of 1.5% in 2025 (1.8% in 2024).

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

14. Stocks

On 31 December 2025 and 2024 the composition of this heading is as follows:

	Thousands of Euros	
	31/12/2025	31/12/2024
Raw materials and other supplies	42,889	45,748
Semi-finished products	35,134	29,283
Goods	13,576	14,393
Finished products	86,533	82,267
Advances to suppliers	-	92
Total	178,132	171,783

The balance of inventories in the preceding table is presented net of balances impaired due to obsolescence and slow turnover, which, at 31 December 2025 and 2024, amounts to €11,032 thousand and €13,685 thousand, respectively.

As of 31 December 2025 and 2024, there were no inventories subject to guarantee, and there were no significant purchase commitments.

15. Trade and other receivables

On 31 December 2025 and 2024 the composition of this heading is as follows:

	Thousands of Euros	
	31/12/2025	31/12/2024
Trade receivables for sales and services	141,907	120,816
Receivable from Covis (Note 12)	2,701	6,243
Other receivables	15,218	27,902
Provision for impairment losses	(1,356)	(3,517)
Total	158,470	151,444

The balance of "Provision for impairment losses" includes €161 thousand at 31 December 2025 (€414 thousand at 31 December 2024) as a result of applying the "expected loss" model (simplified approach) provided for in IFRS 9 (Note 5-j).

The detail of the debtors' balance according to their maturity is as follows:

	Thousands of euros				
	Trade receivables for sales and services	Receivable from Covis	Other receivables	Valuation adjustments for impairment	Total receivables
Not matured	127,454	2,701	15,218	-	145,373
Less than 30 days	10,919	-	-	-	10,919
From 30 to 60 days	1,588	-	-	-	1,588
From 60 to 90 days	746	-	-	(156)	590
From 90 to 180 days	280	-	-	(280)	-
From 180 to 360 days	336	-	-	(336)	-
More than 360 days	584	-	-	(584)	-
Balance as at 31/12/2025	141,907	2,701	15,218	(1,356)	158,470

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

	Thousands of euros				
	Trade receivables for sales and services	Receivable from Covis Pharma	Other receivables	Valuation adjustments for impairment	Total receivables
Not matured	95,713	6,243	27,902	-	129,858
Less than 30 days	18,774	-	-	-	18,774
From 30 to 60 days	3,197	-	-	(385)	2,812
From 60 to 90 days	638	-	-	(638)	-
From 90 to 180 days	1,318	-	-	(1,318)	-
From 180 to 360 days	383	-	-	(383)	-
More than 360 days	793	-	-	(793)	-
Balance as at 31/12/2024	120,816	6,243	27,902	(3,517)	151,444

There is no concentration of credit risk with respect to trade receivables, since the Group has a large number of customers. The bulk of the distribution of proprietary medicinal products is through distributors and wholesalers, wherefore the Group's exposure to retailers is very limited. There are no guarantees on customer balances.

As of 31 December 2025, the percentage of balances with Public Administrations for the hospital business, out of total Customers, amounts to 7.0% (4.7% on 31 December 2024).

Receivables other than financial assets related to Covis (Note 12) are stated at nominal value, since there are no significant differences from their fair value.

The heading of "Other debtors" includes the outstanding amount of the linked loans for research described in Note 19-b).

The balance of the foreign currency receivables totals €37,084 thousand at 31 December 2025 (€34,757 thousand at 31 December 2024). Given the amounts and associated maturities, the potential impact of exchange rate fluctuations is not considered significant.

16. Equity

Share capital

The Parent Company's share capital as at 31 December 2025 is represented by 214,785,198 shares with a par value of €0.12, fully subscribed and paid up (213,468,718 shares as at 31 December 2024).

On 11 June 2025, a total of 1,316,480 new shares from the flexible dividend of the Parent Company were admitted to trading on the Barcelona, Madrid, Bilbao and Valencia stock exchanges. These shares were representative of the holders of 33.3% of the free allotment rights, who opted to receive new shares instead of cash. Consequently, the share capital of the Parent Company following the bonus issue of shares increased by €157,977.60.

On 12 June 2024, a total of 4,074,994 new shares from the flexible dividend of the Parent Company were admitted to trading on the Barcelona, Madrid, Bilbao and Valencia stock exchanges. These shares were representative of the holders of 91.5% of the free allotment rights, who opted to receive new shares instead of cash. Consequently, the share capital of the Parent Company following the bonus issue of shares increased by €488,999.28.

As of 31 December 2025 and 2024, all of the Parent Company's shares were listed on the Spanish stock exchanges, and there were no statutory restrictions on their free transfer. Moreover, pursuant to the shareholders' agreement signed on 28 May 2007, first refusal rights, and put and call options have been granted between ultimate shareholders in the Parent Company with respect to the shares of one of such shareholders.

The shareholders with significant holdings in the share capital of Almirall, S.A., both direct and indirect, in excess of 3% of the share capital, of which the Parent Company is aware, according to the information contained in the official records of the National Securities Market Commission (CNMV) as of 31 December 2025 and 2024, are as follows:

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

<i>Name or company name of the direct shareholder</i>	% Interest 31/12/2025	% Interest 31/12/2024
Grupo Plafin, S.A.U.	44.3%	44.5%
Grupo Corporativo Landon, S.L.	15.6%	15.6%
Norbel Inversiones, S.L.	5.1%	5.1%
Total	65.0%	65.2%

As of 31 December 2025 and 2024, the Parent Company was not aware of any other holdings equal to or greater than 3% of the share capital or voting rights of the Parent Company, which, although less than the established percentage, would enable the exercise of significant influence over the Parent Company.

Legal reserve

The part of the balance of the legal reserve that exceeds 10% of the previously increased capital may be used for a capital increase. Except for the aforementioned purpose, and provided that it does not exceed 20% of the share capital, this reserve may only be used to offset losses if there are no other reserves available that are sufficient for this purpose.

The amount of €4,275 thousand present in this account as at 31 December 2025 and 2024 corresponds to the balance of the Parent Company's legal reserve, which has not been fully funded.

Share premium

The Spanish Capital Companies Act expressly permits the use of the share premium balance to increase capital and does not establish any specific restrictions on the availability of this balance.

As a consequence of the increase in fully-paid share capital resulting from the flexible dividend, this item was increased by the difference between the par value of the shares and the value equivalent to the dividend, which amounts to €14,204 thousand.

After this capital increase, the balance of the share premium item amounts to €596,078 thousand at 31 December 2025 (€581,874 thousand at 31 December 2024).

Other reserves

The itemisation of this account is as follows:

	Thousands of euros	
	31/12/2025	31/12/2024
Reserves for investments in the Canary Islands	-	3,485
Reserves for amortised capital	30,540	30,540
Reserve for merger	4,588	4,588
Revaluation reserve	2,539	2,539
Reserve for share-based payments	3,615	1,127
Other voluntary reserves	804,685	720,102
Subtotal Other reserves of the Parent Company	845,967	762,381
Reserves in consolidated companies	(32,181)	79,329
Treasury shares	(1,933)	(2,781)
Total other reserves	811,853	838,929

There is a limit on distributions that would reduce the balance of reserves to an amount of less than the total outstanding balance of the Parent Company's development costs, which amount to €61.6 million on 31 December 2025 (€33.5 million on 31 December 2024).

- **Reserves for investments in the Canary Islands**

In compliance with the requirements of Law 19/1994, and in order to be able to benefit from the tax incentives that it establishes, the Parent Company allocates to these Reserves for Canary Islands Investments (R.I.C.) part of the profits obtained by the establishment located in the Canary Islands, which at 31 December 2024 is a restricted reserve since the assets of which it consists must remain within the company. During the 2025 financial year, said reserve has been reclassified as a voluntary reserve as it no longer has any restrictions on availability.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

- Reserves for amortised capital

In accordance with the revised text of the Spanish Capital Companies Act, these reserves may only be used subject to the same requirements as for the reduction of share capital.

On 31 December 2025 and 2024, the balance of these reserves amounts to €30,540 thousand.

- Reserve for share-based payments

As described in Note 5-t), in 2024 the Group established new remuneration plans that will be partially equity-settled. The heading "Reserve for share-based payments" includes the amount accrued at 31 December 2025 for the portion to be settled in shares, which amounts to €3,615 thousand (€1,127 thousand at 31 December 2024).

- Liquidity contract and treasury shares

The Parent Company has a liquidity contract with a financial intermediary, effective as from 4 March 2019, with the aim of favouring liquidity and stability of prices of the Company's shares, within the limits established by the General Shareholders' Meeting and by current regulations, in particular, Circular 1/2017, of 26 April, of the National Securities Market Commission (CNMV), on liquidity contracts. This contract means that as at 31 December 2025 the Parent Company holds treasury shares representing 0.06% of the share capital (0.10% at 31 December 2024) and an overall nominal value of €16.3 thousand (€24.6 thousand at 31 December 2024), which have been recognised in accordance with EU-IFRS. The average acquisition price of these shares was €12.9 per share (€8.4 at 31 December 2024). The treasury shares held by the Parent Company are intended to be traded on the market.

Valuation adjustments and other adjustments

The amount of this item was -€28,475 thousand as at 31 December 2025 (-€31,867 thousand at 31 December 2024), and is mainly related to:

- Net accumulated actuarial losses due to recalculations of the valuations of the retirement benefit obligations as a result of changes in the calculation assumptions: -€18,506 million as of 31 December 2025 (-€21,775 million as of 31 December 2024).
- Financial assets measured at fair value through other comprehensive income: in accordance with the application of IFRS 9 (see Note 12), under this heading the Group recorded the impairment losses of the investees Suneva Medical Inc. and Dermelle LLC. The accumulated balance is -€10,092 thousand at the end of both years.

Translation differences

This heading in the accompanying consolidated balance sheet includes the net amount of exchange differences arising due to translation into the Group's reporting currency of the equity of companies with a functional currency other than the euro.

At 31 December 2025 and 2024, the balance of this heading is itemised, by companies, as follows:

	Thousands of Euros	
	31/12/2025	31/12/2024
Almirall Inc / Almirall LLC (USA)	28,954	56,792
Almirall Limited (UK)	(1,051)	(238)
Other subsidiaries	3,572	2,854
Total translation differences	31,475	59,408

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

The changes in the years ending on 31 December 2025 and 2024 were as follows:

	Thousands of euros
Balance as at 31 December 2023	43,827
Variations due to exchange differences	15,581
Balance as at 31 December 2024	59,408
Variations due to exchange differences	(27,933)
Balance as at 31 December 2025	31,475

The change in translation differences generated in 2025 and 2024 is due to the variation due to exchange rate differences, mainly derived from the subsidiaries in the United States, Almirall Inc. and Almirall LLC.

17. Deferred income

The movement and balance of this heading for the financial years ending 31 December 2025 and 2024 are as follows:

	Thousands of Euros
Balance as at 31 December 2023	-
Additions	7,423
Recognition in profit or loss (Note 22)	(2,938)
Balance as at 31 December 2024	4,485
Additions	24,075
Recognition in profit or loss (Note 22)	(2,927)
Balance as at 31 December 2025	25,633

The additions for the financial year ending 31 December 2025 correspond to the amount of €24.1 million for the renewal of rights over a certain product brand for territories, mainly in Eastern Europe. This agreement signed in July 2025 will come into effect on 1 January 2026, once the existing agreement has expired. Under the terms of this agreement, the Group received €20 million upon signing the contract, royalties will be received, and the supply of the product is planned for the financial years 2026 to 2030; also, at the beginning of financial year 2031, a final payment of €5 million will be received (see Note 12). Said amount of €20 million received in financial year 2025 and the net present value of the €5 million to be received in 2031 will be allocated linearly in the heading of "Net turnover" in the consolidated income statement during the period 2026–2030.

The additions in 2024 correspond to the difference between the nominal value and the fair value of the loans granted by the CDTI (Note 19-b).

The recognition in profit or loss for 2025 and 2024 corresponds to the income accrued on the basis of the progress of each of the financed projects (mainly between 1 and 2 years), which is recorded under the heading "Other income" in the consolidated income statement (Note 22).

18. Financial debts

As detailed in Note 5-j), the Group classifies its financial liabilities into the following measurement categories:

- Financial liabilities measured at amortised cost: this heading includes mainly unsecured bonds, bank loans and revolving credit facilities. At the date of initial application, the Group's business model is to maintain this financing to pay contractual cash flows that represent only payments of principal and interest on the principal amount.
- Financial liabilities measured at fair value with variations in the profit and loss account: The Group currently holds derivative financial instruments in this category, as described in Note 5-k) and further below in this note.

The composition of the debts with credit institutions and other financial liabilities as of 31 December 2025 and 2024 was as follows:

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

	Limit	Balance drawn down (*)	Current	Non-current			
				2027	2028	Rest	Total
Financial liabilities at amortised cost							
Credit facilities	275,000	-	-	-	-	-	-
Loans with credit institutions	80,000	35,000	10,000	10,000	10,000	5,000	25,000
Senior unsecured bonds	250,000	245,035	-	-	-	245,035	245,035
Financial liabilities at fair value through profit or loss							
Liabilities for derivative financial instruments	N/A	2,833	2,833	-	-	-	-
Accrued interest to be paid	N/A	823	823	-	-	-	-
Total as at 31 December 2025	605,000	283,691	13,656	10,000	10,000	250,035	270,035

(*) Balance drawn down net of issuance costs.

	Limit	Balance drawn down (*)	Current	Non-current			
				2026	2027	Rest	Total
Financial liabilities at amortised cost							
Credit facilities	275,000	-	-	-	-	-	-
Loans with credit institutions	80,000	45,000	10,000	10,000	10,000	15,000	35,000
Senior unsecured bonds	300,000	297,993	-	297,993	-	-	297,993
Financial liabilities at fair value through profit or loss							
Liabilities for derivative financial instruments	N/A	2,046	2,046	-	-	-	-
Accrued interest to be paid	N/A	2,327	2,327	-	-	-	-
Total at 31 December 2024	655,000	347,366	14,373	307,993	10,000	15,000	332,993

(*) Balance drawn down net of issuance costs.

Senior unsecured bonds

On 17 December 2025, the Parent Company proceeded to conclude and disburse an issuance of senior unsecured bonds for an aggregate nominal amount of €250 million, at a fixed annual interest rate of 3.75%, maturing on 15 June 2031 (5 and a half years). The bonds were placed among qualified investors by BNP Paribas and JP Morgan AG, as coordinating entities. The effective interest rate of these bonds is 4.2%.

The debt from these bonds is stated at the nominal amount (€250 million) net of issuance costs (which amounted to €5.0 million), which will be recorded over the life of the bonds at amortised cost using the effective interest method.

The funds obtained were used to prematurely cancel the obligations issued in 2021 (with a nominal value of €300 million), which were due on 22 September 2026, together with an additional €55 million (the €50 million difference between the nominal values plus issuance costs) that the Group had in cash and cash equivalents. These obligations accrued a fixed annual interest rate of 2.125% (2.5% effective rate).

Debts with credit institutions

Details of the debts with credit institutions as of 31 December 2025 and 2024 are as follows:

	Limit	Balance drawn down	Final maturity	Nominal interest rate	Effective interest rate
Debts with credit institutions					
Revolving credit facility	275,000	-	02/02/2028	3.48% (Euribor + Margin)	3.48%
European Investment Bank Loan	80,000	35,000	17/04/2029	1.65%	1.65%
Total as at 31 December 2025	355,000	35,000			

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

	Limit	Balance drawn down	Final maturity	Nominal interest rate	Effective interest rate
Debts with credit institutions					
Revolving credit facility	275,000	-	02/02/2028	4.87% (Euribor + Margin)	4.87%
European Investment Bank Loan	80,000	45,000	17/04/2029	1.65%	1.65%
Total at 31 December 2024	355,000	45,000			

On 17 July 2020, the Parent Company arranged a revolving credit facility for €275 million, for an initial term of three years with the possibility of an extension for an additional year (this renewal was granted on 30 June 2021), and this facility was earmarked for general corporate purposes. On 2 February 2024, this policy was novated for the same amount, maintaining the same contractual conditions and for an initial term of 4 years (with the possibility of an extension of 1 additional year), intended for general corporate uses. The credit facility contract obliges the Parent Company to comply with a series of covenants, including most notably compliance with a certain ratio of "Consolidated net financial debt / consolidated EBITDA". This covenant is complied with 31 December 2025 and 2024.

On 27 March 2019, the Parent Company arranged a loan facility with the European Investment Bank (EIB) for up to €120 million to fund its research and development efforts, with the objective of providing cutting-edge innovation and differentiated therapies in the area of medical dermatology. On 17 April 2019, the first tranche of €80 million was granted, with 32 equal repayments of principal between 17 July 2021 and 17 April 2029, with the latter date being the final maturity. Due to the issue of new debt in 2021, the interest rate increased by 0.30%. The loan agreement requires the Parent Company to comply with a series of covenants, including most notably compliance with a "Consolidated net financial debt / consolidated EBITDA" ratio and a "Financial leverage of subsidiaries / consolidated EBITDA" ratio. Both covenants are complied with 31 December 2025 and 2024.

Derivative financial instruments

On 10 May 2018, the Ordinary General Meeting of Shareholders arranged the completion of a swap transaction of interest rate and shares ("Equity swap"). This transaction entered into force by means of a contract dated 11 May 2018 with Banco Santander, S.A., whereby Almirall S.A. is bound to pay variable interest to the bank as compensation and Banco Santander, S.A. undertakes, as acquirer of underlying ordinary shares of the company Almirall S.A. with a maximum nominal limit of 2.99% of the share capital (5,102,058 shares or €50 million), to hand over the dividend received for its investment in Almirall S.A. Said instrument was renewed in December 2025 with Caixabank, S.A. for a term of 2 years.

In addition, when the fair value is less than 75% of the cost value, the Group must offset the loss by contributing cash to the bank only for the difference between the % decrease and 75% of the cost value (in this case reducing the recognised value of the derivative). Once a settlement has been made, if the fair value recovers from the last settlement, the Group will recover the payments made on a monthly basis (always limited to the acquisition cost and the settlements previously made by Caixabank, S.A.). Once the value is greater than or equal to 75% of the cost value, the Group will have recovered all the previously made settlements. For this reason, the Group has opted to classify this asset/liability as current.

Consequently, under the heading "Assets resulting from derivative financial instruments" (in the case of unrealised gains) or "Liabilities resulting from derivative financial instruments" (in the case of unrealised losses), the fair value of the derivative has been recognised, which corresponds to the difference between the fair value of the underlying asset and the acquisition cost of the same for Caixabank, S.A. (2,510,952 shares equivalent to €35.1 million, corresponding to 1.2% of the share capital of the Parent Company).

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

During the 2025 financial year, the Group has recovered all disbursements made to date (€12,349 thousand). Below are the impacts as at 31 December 2025 and 2024:

	Thousands of euros	
	31/12/2025	31/12/2024
Underlying asset:		
Fair value	32,240	20,678
Acquisition cost	35,073	35,073
Capital gain / (capital loss)	(2,833)	(14,395)
Disbursements made to date	-	12,349
Asset / (liability) per derivative financial instrument	(2,833)	(2,046)
Profit / (Loss) for the year (Note 22)	11,562	(477)

Other financial debt considerations

At the drafting date of these consolidated financial statements, the Parent Company's Board of Directors considers that no breach of the aforementioned obligations (including the aforementioned series of covenants) has occurred.

The interest accrued and payable at 31 December 2025 amounts to €823 thousand (€2,327 thousand at 31 December 2024), and it corresponds mainly to the interest accrued on debts with credit institutions.

The average cost of debt for the years ending on 31 December 2025 and 2024 was 1.4% and 1.5%, respectively. The Group's exposure to interest rate risk is limited at 31 December 2025 and 2024 (Note 32).

Moreover, in application of the amendment to IAS 7, below we provide a reconciliation of the cash flows arising from financing activities with the corresponding liabilities in the opening and closing consolidated balance sheet, separating the movements that involve cash flows from those that do not.

	Balance as at 1/01/2025	Cash flows	Interest accrued	Changes in fair value	Balance as at 31/12/2025
Financial liabilities at amortised cost					
Credit facilities	-	-	-	-	-
Loans with credit institutions	45,000	(10,000)	-	-	35,000
Senior unsecured bonds	297,993	(55,000)	2,042	-	245,035
Financial liabilities at fair value through profit or loss					
Liabilities for derivative financial instruments	2,046	12,349	-	(11,562)	2,833
Accrued interest to be paid	2,327	(11,462)	9,958	-	823
Total Financial debt	347,366	(64,113)	12,000	(11,562)	283,691

	Balance as at 1/01/2024	Cash flows	Interest accrued	Changes in fair value	Balance as at 31/12/2024
Financial liabilities at amortised cost					
Credit facilities	-	-	-	-	-
Loans with credit institutions	55,000	(10,000)	-	-	45,000
Senior unsecured bonds	296,851	-	1,142	-	297,993
Financial liabilities at fair value through profit or loss					
Liabilities for derivative financial instruments	1,569	-	-	477	2,046
Accrued interest to be paid	2,399	(10,537)	10,465	-	2,327
Total Financial debt	355,819	(20,537)	11,607	477	347,366

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

19. Trade payables and Other liabilities

a) Trade payables

On 31 December 2025 and 2024 the composition of this item is as follows:

	Thousands of Euros	
	31/12/2025	31/12/2024
Suppliers	69,703	80,224
Trade payables	124,150	106,301
Total short-term trade payables	193,853	186,525

The balance of this heading is mainly composed of suppliers of active ingredients and proprietary medicinal products, either companies that specialise in manufacturing for third parties or the laboratories that own the licensed products (Note 9); suppliers of R&D services (for the management of clinical trials or as a consequence of a development agreement); suppliers of logistics, regulatory, marketing and market access services; and suppliers of other services that support the entire value chain in terms of information technology, consulting and human resources.

In addition, this heading includes the amounts pending payment in the short term for contributions to health systems, as detailed in Note 5-q).

b) Other current and non-current liabilities

On 31 December 2025 and 2024 the composition of this item is as follows:

	Thousands of Euros				
	Current	Non-current			Total
		2027	2028	Rest	
Loans linked to research	278	469	1,363	18,431	20,263
Debts for purchases of fixed assets	64,193	-	8,636	-	8,636
Remuneration to be paid	39,708	4,413	2,885	1,366	8,664
Long-term tax liabilities	-	-	-	6,795	6,795
Other debts	167	-	-	4,148	4,148
Total as at 31 December 2025	104,346	4,882	12,884	30,740	48,506

	Thousands of Euros				
	Current	Non-current			Total
		2026	2027	Rest	
Loans linked to research	1,121	327	516	19,272	20,115
Debts for purchases of fixed assets	62,898	-	-	8,224	8,224
Remuneration to be paid	38,624	2,069	4,895	1,508	8,472
Long-term tax liabilities	-	-	-	6,573	6,573
Other debts	311	-	-	4,454	4,454
Total at 31 December 2024	102,954	2,396	5,411	40,031	47,838

Loans linked to research refer mainly to subsidised-interest loans and/or grace periods granted by the Ministry of Science and Technology to promote research, and are presented as described in Note 5-j). The granting of these loans is subject to compliance with carrying out certain investments and expenses during the years for which they are granted, and the loans mature between 2023 and 2041. In the 2025 financial year, no new loans of significant amount have been granted. In the first half of 2024, various loans were granted for a nominal value of €26.0 million. The difference between the nominal value and the fair value of said loans is recorded under deferred income (Note 17).

Debts for purchases of fixed assets refer basically to disbursements pending the acquisition of goods, products and marketing licenses contracted in the fiscal year and prior years. The current balance at 31 December 2025 mainly includes the outstanding payment with Sun Pharma described in Note 9 (equivalent to a total of €46.8 million), which is pending payment as of the preparation date of these

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

consolidated annual accounts. The current balance at 31 December 2024 mainly included the outstanding payments with Sun Pharma, Eloxx Pharmaceuticals Inc. and MC2 Therapeutics described in Note 9 (equivalent to a total of €49.5 million).

As at 31 December 2025 and 2024, the balance of Remunerations to be paid mainly includes the balances to be paid to employees for the accrued portions of special payments, as well as the Group's bonuses for achieving targets and the provision for long-term remunerations, both the SEUS plan and the Performance Shares Plan (see Note 5-t)).

As a result of the application of IFRIC 23 "Uncertainty over income tax treatments" (Note 5-r)), at 31 December 2025, €6,795 thousand are classified as "Long-term tax liabilities" (€6,573 thousand at 31 December 2024).

There are no significant differences between the fair value of the liabilities and the recognised amount.

20. Retirement benefit obligations

The retirement benefit obligations are related mainly with the subsidiaries Almirall Hermal GmbH, Almirall AG, and Polichem S.A., and are related with unfunded plans (there are no assets assigned to these plans), as described in Note 5-m).

The changes in the defined benefit obligation were as follows:

	2025	2024
At 1 January	58,581	60,481
Current services cost	171	182
Interest cost	1,898	1,866
Contributions from plan participants	-	8
Actuarial losses / (gains)	(5,769)	(1,606)
Benefits paid	(2,745)	(2,503)
Other changes	(27)	153
At 31 December	52,109	58,581

The amount recorded as actuarial profits or losses mainly reflects the impact of the variation in the discount rate used in the actuarial calculations in the years 2025 and 2024 based on the change in interest rates.

The main assumptions used for the calculation of the actuarial valuation of the commitment with Almirall Hermal, GmbH, which represents the majority of the liability amounting to €51.8 million and €57.8 million at the end of financial years 2025 and 2024, respectively, are as follows:

Almirall Hermal GmbH	2025	2024
Mortality tables	Richttafeln 2018 G von K. Heubeck	Richttafeln 2018 G von K. Heubeck
Discount rate	3.97%	3.36%
Rate of salary increase	3.50%	3.50%
Rate of benefit increase	2.00%	2.10%
Turnover rate	Variable according to age and gender	Variable according to age and gender
Retirement age	65 - 67	65 - 67

Sensitivity to changes in the key assumptions, weighted in accordance with the following table, would not have a significant effect on the total pension liability:

	Change in the assumption
Discount rate	Increase/decrease by 0.5%
Rate of inflation	Increase/decrease by 0.5%
Rate of salary increases	Increase/decrease by 0.5%
Mortality rate	Increase in 1 year

These changes in the assumptions are reasonable with those indicated by the actuarial reports, which the Group's Management considers appropriate.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

The amounts recognised in the consolidated income statement are as follows:

	2025	2024
Current service cost	171	182
Interest cost	1,898	1,866
Total	2,069	2,048

Finally, in the case of the defined contribution pension plans, the contributions are made to non-related entities, such as insurance companies, and the amount recognised as an expense in 2025 and 2024 amounted to €3.9 and €4.1 million, respectively.

21. Provisions

The changes in 2025 and 2024 under the "Provisions" heading in the accompanying consolidated balance sheet were as follows:

	Thousands of Euros	
	2025	2024
Balance as at 1 January	8,447	9,491
Additions and provisions	365	14
Reclassifications	(75)	-
Translation differences	(487)	248
Reversals	(319)	(1,306)
Balance as at 31 December	7,931	8,447

This heading of the consolidated balance sheet refers mainly to the Group's estimate of the disbursements that it would have to make in the future to meet other liabilities arising from the nature of its business.

22. Income and expenses

Net turnover

As mentioned in Note 5-p), the Group separates net turnover into two concepts and three major segments:

	Thousands of Euros	
	2025	2024
Sales of products	1,076,659	970,893
Income from granting licenses	31,425	14,828
Net turnover	1,108,084	985,721

	Thousands of Euros	
	2025	2024
Marketing through own network	955,301	863,810
Marketing through licensees	111,494	97,226
Manufacturing for third parties and intermediation	41,289	24,685
Net turnover	1,108,084	985,721

The net turnover amount by geographic area, together with details of the main countries in which it is obtained, is shown below:

	Thousands of Euros	
	2025	2024
Spain	328,928	305,232
Europe and Middle East	683,536	576,012
America, Asia and Africa	95,620	104,477
Net turnover	1,108,084	985,721

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

	Thousands of Euros	
	2025	2024
Spain	328,928	305,232
Germany	319,856	274,981
Italy	101,826	87,126
France	50,535	38,689
United States	45,195	55,396
United Kingdom	37,242	28,885
Other countries	224,502	195,412
Net turnover	1,108,084	985,721

Finally, the contribution from the main therapeutic areas of the various products sold by the Group is detailed:

	Thousands of Euros	
	2025	2024
Dermatology and others	669,428	548,025
Respiratory	100,077	92,718
Gastrointestinal and metabolism	90,686	98,179
Central nervous system	89,625	82,441
Cardiovascular	85,143	89,422
Musculoskeletal	33,297	39,826
Other therapeutic specialities	39,828	35,110
Net turnover	1,108,084	985,721

Other income

The itemisation of this heading is as follows:

	Thousands of Euros	
	2025	2024
Income due to agreement with AZ/Covis (Note 12)	-	2
Allocation of deferred income (Note 17)	2,927	2,938
Others	3,521	1,966
Total	6,448	4,906

Supplies

The itemisation of this heading is as follows:

	Thousands of Euros	
	2025	2024
Purchases	270,990	242,716
Change in stocks of finished or semi-finished products	(10,117)	(10,593)
Change in stocks of raw materials and goods	3,676	6,272
Total	264,549	238,395

Staff costs

The composition of staff costs is as follows:

	Thousands of Euros	
	2025	2024
Payroll and salaries	198,181	183,584
Social security payable by the company	38,909	34,618
Compensation payments	8,369	1,428
Other welfare expenses	18,325	15,301
Total	263,784	234,931

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

In fiscal years 2025 and 2024, the average number of employees of the Group, distributed by professional category and gender, is as follows:

	2025			2024		
	Men	Women	Total	Men	Women	Total
Directors	1	-	1	1	-	1
Executives	70	49	119	64	42	106
Managers	106	102	208	105	94	199
Technical staff	509	705	1,214	472	664	1,136
Administrative staff	275	263	538	267	273	540
Others	-	2	2	-	2	2
Total	961	1,121	2,082	909	1,075	1,984

At year-end 2025 and 2024, the staff is as follows:

	31 December 2025			31 December 2024		
	Men	Women	Total	Men	Women	Total
Directors	1	-	1	1	-	1
Executives	72	49	121	66	46	112
Managers	106	109	215	106	97	203
Technical staff	519	713	1,232	488	688	1,176
Administrative staff	273	264	537	271	261	532
Others	-	2	2	-	2	2
Total	971	1,137	2,108	932	1,094	2,026

Likewise, at the end of the 2025 and 2024 financial years, there were 10 directors, of which 4 were women and 6 were men.

At 31 December 2025, the number of employees with a disability equal to or greater than thirty-three per cent (or an equivalent local qualification) totalled 42 people (40 people at 31 December 2024).

As of 31 December 2025 and 2024, the number of Group employees engaged in research and development activities amounted to 311 and 288 people, respectively.

Other operating expenses

The composition of other operating expenses is as follows:

	Thousands of Euros	
	2025	2024
R&D activities	96,000	79,005
Leases and fees	72,950	54,949
Repairs and maintenance	23,258	22,002
Independent professional services	29,027	27,413
Transport	17,131	15,131
Insurance premiums	4,257	3,897
Bank services and similar	912	765
Congresses and other promotional activities	96,767	100,264
Supplies	4,982	5,041
Other services	42,166	37,988
Other taxes	2,852	1,810
Total	390,302	348,265

The heading of leases and royalties includes royalties linked to several licence agreements described in Note 9. The amounts corresponding to 2025 and 2024 were €56.0 and €39.8 million, respectively. The increase in this type of expenditure is mainly explained by the increase in sales of products marketed under the brands Ilumetri, Ebglyss and Wyzora.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Net change in valuation adjustments

The composition of this heading is as follows:

	Thousands of Euros	
	2025	2024
Variation in valuation correction due to impairments of accounts receivable	1,364	(910)
Change in stock valuation adjustment	(400)	(389)
Change in other current provisions	(506)	604
Total	458	(695)

Net gains / (losses) on disposal of assets

The itemisation of net gains/ (losses) on disposal of non-current assets in fiscal years 2025 and 2024 is as follows:

	Thousands of Euros			
	2025		2024	
	Gains	Losses	Gains	Losses
For disposal or retirement of intangible assets	-	(207)	-	(2,692)
For disposal or retirement of property, plant and equipment	28	(20)	-	(802)
	28	(227)	-	(3,494)
Net gains (losses) on disposal of assets	(199)		(3,494)	

The losses recorded in 2024 related to the termination of the development contract and discontinuation of a product (Altabax) that was part of the takeover of Aqua Pharmaceuticals, now Almirall LLC (both mentioned in Note 9), and to the sale of land mentioned in Note 11.

Financial income and expenses

The breakdown of financial income and expenses in fiscal years 2025 and 2024 is as follows:

	Thousands of Euros			
	2025		2024	
	Income	Expenses	Income	Expenses
Bond issuance costs (Note 18)	-	(8,586)	-	(7,439)
Financial and similar income / (expenses)	6,848	(8,362)	7,189	(8,219)
Financial assets valuation adjustment (Note 12)	-	-	463	-
Change in fair value of financial instruments (Note 18)	11,562	-	-	(477)
Exchange rate differences	-	(65)	-	(1,105)
	18,410	(17,013)	7,652	(17,240)
Financial result	1,397		(9,588)	

The breakdown of "Other finance income/(expenses) and similar" includes financial expenses derived from bank loans, as well as the impact of the financial restatement of liabilities carried at amortised cost and the financial cost of the pension payments, with the exception of the financial cost of the senior unsecured bonds (as described in Note 18), which are included in the breakdown of "Bond issuance costs" (€8.6 million and €7.4 million in 2025 and 2024, respectively). On the other hand, the income corresponds to interest amounting to €6.8 million (€7.2 million in 2024), which mainly comes from investments in deposits made during the financial year, although by the end of the financial year all had matured.

In 2024, the heading "Valuation adjustment of financial assets" included the income related to the partial repayment of the loan with Celling Aesthetics LLC, as described in Note 12.

In 2025 and 2024, the breakdown of "Changes in fair value of financial instruments" includes mainly the restatement of the fair value of the Equity Swap described in Note 18.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Impairment losses on property, plant and equipment, intangible assets and

In the 2025 financial year, this item includes the reversal of the impairment of certain software assets that have been written off due to disuse, as mentioned earlier.

In 2024, this heading included the net amount resulting from the impairment tests performed on the products marketed under the Seysara and Cordran Tape brands, which form a part of the Allergan CGU portfolio, for a total amount of €10.0 million (see Note 9).

Foreign currency transactions

The amounts for the transactions carried out in foreign currencies are as follows:

	Amount in euros (thousands)			
	Expenses		Income	
	2025	2024	2025	2024
Swiss franc	11,405	10,339	22,738	18,595
Czech koruna	1,468	1,120	7,619	4,185
Danish krone	1,796	1,333	4,716	1,464
Pound sterling	20,506	17,474	36,451	29,297
Japanese Yen	3,272	3,520	224	565
Norwegian Krone	188	306	4,796	4,226
Polish Zloty	1,689	1,350	9,338	6,390
Renminbi	387	733	-	-
Swedish Krona	909	592	5,212	3,079
US Dollar	95,498	70,974	55,357	73,833
Other currencies	902	595	-	138

Remuneration of auditors

During fiscal years 2025 and 2024, the fees for auditing services and other services provided by the Group's auditor, KPMG Auditores S.L., or by other companies in the auditor's network, were as follows:

Entities (Thousands of Euros)	Year	Audit and related services		Tax services	Other services
		Audit services	Professional services related to auditing		
KPMG Auditores, S.L.	2025	243	274	-	116
Other companies in the PwC network		310	59	12	-
Total		553	333	12	116
KPMG Auditores, S.L.	2024	235	110	-	81
Other companies in the PwC network		307	55	-	-
Total		542	165	-	81

In 2025 and 2024, other auditors have accrued €55 thousand and €118 thousand, respectively, in relation to the audit work of investee companies.

The heading "Audit services" includes the fees corresponding to the audit of the individual and consolidated financial statements of Almirall, S.A. and of the companies that form part of its group.

The item "Professional services related to auditing" mainly includes fees derived from the limited review of the Group's interim consolidated financial statements and the review of information related to the ICFR, as well as, in the case of 2025, fees for the issue of a "comfort letter" linked to the issuance of the senior unsecured bonds detailed in Note 18.

The heading "Other services" includes the fees for the review of the Consolidated Statement of Non-Financial Information and Sustainability Information.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

23. Tax situation

Consolidated Tax Group

The Parent Company is subject to Corporate Income Tax under the Tax Consolidation regime, as described in Note 5-r). Corporate income tax is calculated on the basis of the economic or accounting result, obtained by applying the applicable financial reporting regulatory framework, which does not necessarily coincide with the tax result, which in turn is understood as the taxable income.

The rest of the Group's subsidiaries file individual tax returns in accordance with the tax regulations applicable in each country.

Fiscal years subject to tax inspection

The Parent Company and the companies forming a part of the Spanish tax group are currently open to audits for fiscal years 2021 to 2024 regarding Corporate Income Tax and for fiscal years 2022 to 2025 for all other applicable taxes.

During the 2022 financial year, the initiation of an inspection procedure concerning Almirall Inc. and its subsidiaries (United States) was communicated. This inspection is related to the Corporate Income Tax for 2015, 2016, 2018 and 2020. This inspection was completed in fiscal year 2025, with no significant aspect arising.

During the 2025 financial year, no inspections other than those mentioned above were initiated.

The Group's foreign companies are currently being audited for the corresponding years, in each of the local legislations, regarding the applicable taxes.

In general, due to the different ways in which the tax regulations may be interpreted, the results of the inspections that are being carried out, or that may be carried out in the future by the tax authorities, for the years subject to verification, may give rise to tax liabilities of an amount that cannot be objectively quantified at present. In the opinion of the Parent Company's Board of Directors, however, the possibility of significant liabilities arising in this respect, in addition to those recognised, is remote.

Income tax recognised

Income taxes recognised in the consolidated income statement and in equity in fiscal years 2025 and 2024, are as follows:

	Thousands of Euros	
	Expense / (Income)	
	2025	2024
Corporate Income Tax:		
- Recognised in the consolidated income statement	28,294	16,351
- Recognised in equity	2,377	268
Total	30,671	16,619

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Reconciliation of accounting and tax results

Presented below is the reconciliation between the income tax expense resulting from applying the general tax rate in force in Spain and the expense recorded for the aforementioned tax:

	Thousands of Euros	
	2025	2024
Consolidated pre-tax profit or loss	74,448	26,498
Permanent differences:		
Increase	422,205	533,413
Decrease	(401,173)	(503,718)
Adjusted accounting profit	95,480	56,193
Tax rate	25%	25%
Gross Tax	23,870	14,048
Deductions:		
Deductions applied and/or regularised in the fiscal year and other consolidation adjustments	(6,195)	(16,009)
Corporate Income Tax for Almirall, S.A. paid abroad	648	61
Effect on income tax expense of subsidiaries in losses	8,120	12,699
Others	1,836	3,856
Accrued cost for theoretical tax	28,279	14,655
Effect of rate difference between countries	409	2,072
Other changes	(394)	(376)
Expense / (Income) accrued for Corporate Income Tax	28,294	16,351

In relation to financial year 2025:

- The positive permanent differences of €422.2 million mainly relate to provisions for shareholdings in subsidiaries primarily in the US business, for an aggregate amount of €83.4 million (impacting the financial statements of Almirall Inc. and Almirall S.A.). In addition, in 2025 various subsidiaries distributed dividends in the aggregate amount of €330.8 million received between Almirall S.A., Almirall Holding Iberia, S.L. and Poli Group Holding, S.r.l., which were also adjusted as a permanent difference.
- The negative permanent differences, €401.2 million correspond, in turn, to consolidation adjustments due to the elimination of valuation adjustments on subsidiaries and dividends between subsidiaries, both mentioned in the preceding paragraph. The remaining amount mainly corresponds to the partial bonus of certain income linked to the exploitation of intellectual property by the subsidiary company Polichem S.A.

In relation to financial year 2024:

- The positive permanent differences of €533.4 million mainly related to provisions for shareholdings in subsidiaries primarily in the US business, for an aggregate amount of €54.3 million (impacting the financial statements of Almirall Inc. and Almirall S.A.). In addition, in 2024 various subsidiaries distributed dividends in the aggregate amount of €472.2 million received between Almirall S.A., Almirall Holding Iberia, S.L. and Poli Group Holding, S.r.l., which were also adjusted as a permanent difference.
- The negative permanent differences, €503.7 million corresponded, in turn, to consolidation adjustments due to the elimination of valuation adjustments on subsidiaries and dividends between subsidiaries, both mentioned in the previous paragraph. The remaining amount mainly corresponded to the partial bonus of certain income linked to the exploitation of intellectual property by the subsidiary company Polichem S.A.

The amount of the deductions applied and/or adjusted in Spain during the 2025 and 2024 fiscal years include, among other concepts, the partial monetisation of the research and development deduction generated in fiscal years 2024 and 2023, respectively. These amounts are detailed in the section on deductions due to maturity.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

The Group has complied with the following requirements in order to be able to apply such monetisation:

- At least one year has elapsed since the end of the tax period in which the deduction was generated, without the deduction having been applied.
- The average number of employees or, alternatively, the average number of employees assigned to research and development and technological innovation activities has not reduced since the end of the tax period in which the deduction was generated until the end of the period referred to in the following paragraph.
- An amount equivalent to the deduction applied or paid is used for research and development and technological innovation expenses or for investments in tangible fixed assets or intangible fixed assets exclusively assigned to such activities, excluding real estate, within 24 months following the end of the tax period in whose tax return the corresponding application or request for payment is made.
- The entity has obtained a reasoned report on the qualification of the activity as research and development or technological innovation or a prior agreement on the valuation of the expenses and investments corresponding to these activities.

The effect on the tax expense of subsidiaries in losses mainly includes the effect of the losses of the US subsidiaries (Almirall LLC and Almirall Inc), which do not record tax credit assets on their balance sheet.

The nature and amount of the incentives applied in 2025 and 2024 and those pending deduction as of 31 December 2025 and 2024 for the Spanish tax group are as follows:

Nature	Thousands of Euros			
	2025		2024	
	Compensated	Pending compensation	Compensated	Pending compensation
Research and Development	8,527	347,694	6,250	354,427
Technological Innovation	-	3,323	-	3,323
International Double Taxation	103	-	-	54
Reinvestment of extraordinary profits	-	67	-	67
Donations	-	390	-	358
Temporary measures	-	325	-	331
Total deductions credited	8,630	351,799	6,250	358,560
Tax loss carryforwards (quota)	1,983	99,057	198	98,203
Total tax credits credited	10,613	450,856	6,448	456,763

There are no significant incentives (deductions) in the other tax jurisdictions where the Group operates.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

The period for application of the deductions for scientific research and technological innovation activities that have not yet been applied is 18 years from their origin, and the application of these is limited to 50% of the tax liability according to the current legislation, whenever the deduction that the Parent Company generates each year is expected to exceed 10% of the total tax liability. The expiry dates of the deductions for Research and Development are detailed below:

Year generation	Cut-off year of application	Thousands of Euros			
		2025		2024	
		Compensated	Pending compensation	Compensated	Pending compensation
2007	2025	2,277	-	-	23,710
2008	2026	-	34,841	-	34,841
2009	2027	-	26,883	-	26,883
2010	2028	-	34,628	-	34,628
2011	2029	-	35,845	-	35,845
2012	2030	-	32,841	-	32,841
2013	2031	-	28,660	-	28,660
2014	2032	-	23,387	-	23,387
2015	2033	-	12,247	-	12,247
2016	2034	-	11,521	-	11,521
2017	2035	-	9,824	-	9,824
2018	2036	-	8,908	-	8,908
2019	2037	-	9,786	-	9,786
2020	2038	-	7,823	-	7,823
2021	2039	-	7,470	-	7,470
2022	2040	-	10,444	-	10,444
2023	2041	-	10,570	6,250	10,570
2024	2042	6,250	18,789	-	25,039
2025	2043	-	23,227	-	-
Total R&D deductions		8,527	347,694	6,250	354,427

There is no time limit for the application of the deductions to avoid international double taxation that have not yet been applied. However, current legislation on corporate income tax stipulates that the application is limited to 50% of the total tax liability. For all other deductions, the deadline is 15 years immediately and successively as from the generation thereof.

In relation to tax credits by tax base, a breakdown of the most significant tax jurisdictions is given below:

Jurisdiction tax	Year generation	Thousands of Euros			
		2025		2024	
		Compensated	Pending compensation	Compensated	Pending compensation
Spain	2017	1,983	2,150	198	4,133
	2019	-	26,526	-	26,526
	2021	-	814	-	814
	2024	-	743	-	743
United States	2017	-	56	-	67
	2019	-	383	-	438
	2020	-	1,717	-	1,773
	2021	-	11,734	-	13,290
	2022	-	15,127	-	17,137
	2023	-	17,402	-	19,713
	2024	-	11,871	-	13,569
2025	-	10,534	-	-	
Tax loss carryforwards (quota)		1,983	99,057	198	98,203

These tax loss carryforwards have no time limit for application, with the exception of €10,775 thousand corresponding to state tax loss carryforwards generated in the United States, whose application limit is between 2027 and 2044.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Deferred tax assets and liabilities

The breakdown of deferred tax assets and liabilities recorded on the consolidated balance sheet is as follows:

	Thousands of Euros	
	31/12/2025	31/12/2024
Deferred tax assets (net)	(1,671)	1,157
Deferred tax liabilities	(60,639)	(64,992)
Tax loss carryforwards	30,233	32,216
Deductions to be applied	151,961	155,487
Deferred tax assets (net)	119,884	123,868

The gross movement in the deferred tax assets and liabilities account has been as follows:

	Thousands of Euros	
	2025	2024
At 1 January	123,868	109,841
Credit to the consolidated profit and loss account	4,643	20,545
Partial monetisation R&D deductions	(6,250)	(6,250)
Tax (Charged)/ Paid to consolidated equity	(2,377)	(268)
At 31 December	119,884	123,868

Pursuant to the tax regulations in force in the different countries in which the consolidated entities are located, certain timing differences have arisen in 2025 and 2024 that must be taken into account when quantifying the corresponding income tax expense.

The breakdown of deferred tax assets and liabilities (net) by concept is as follows:

	Thousands of Euros			
	31/12/2025		31/12/2024	
	Differences in cumulative tax bases	Cumulative effect on tax liability	Differences in cumulative tax bases	Cumulative effect on tax liability
Deferred tax assets (net):				
Depreciation of assets	48,665	12,166	28,622	7,156
Provisions	47,439	11,860	39,974	10,363
Retirement benefit obligations	20,248	5,062	25,576	8,078
Stock valuation	31,616	7,904	36,532	9,133
Freedom of amortisation R.D. 27/84, 2/85, 3/93	(9,014)	(2,253)	(9,414)	(2,354)
Goodwill amortisation	(137,651)	(34,413)	(128,048)	(32,012)
Others	(7,985)	(1,997)	3,172	793
Deferred tax assets (net):	(6,682)	(1,671)	(3,586)	1,157
Deferred tax liabilities (net):				
Capitalisation of intangible assets	2,352	588	2,408	602
Allocation of capital gains to assets in business combinations	188,728	47,182	208,511	52,118
Goodwill amortisation	42,488	10,622	42,488	10,622
Others	8,988	2,247	6,600	1,650
Deferred tax liabilities (net)	242,556	60,639	260,007	64,992

The amount of net deferred tax assets that will reverse in a period of less than 12 months amounts to €9.7 million at 31 December 2025.

In accordance with IAS 12, the Group presents net deferred tax assets and liabilities for each of the tax jurisdictions in which the Group operates, although this only occurs with those related to the Spanish consolidated tax group.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

The breakdown of deferred tax assets and liabilities by jurisdiction at 31 December 2025 and 2024 is as follows:

Jurisdiction tax	Thousands of Euros					
	31/12/2025			31/12/2024		
	Posted	Not recorded	Total	Posted	Not recorded	Total
Net deferred tax assets:						
Spain	(34,185)	-	(34,185)	(34,374)	-	(34,374)
Germany	5,538	-	5,538	7,988	-	7,988
United States	2,608	35,136	37,744	2,696	42,677	45,373
Rest (*)	(36,271)	-	(36,271)	(40,145)	-	(40,145)
Total	(62,310)	35,136	(27,174)	(63,835)	42,677	(21,158)
Tax loss to carry forward:						
Spain	30,233	-	30,233	32,216	-	32,216
United States	-	68,824	68,824	-	65,987	65,987
Total	30,233	68,824	99,057	32,216	65,987	98,203
For deductions pending offset						
Spain	151,961	199,838	351,799	155,487	196,259	351,746
Total	151,961	199,838	351,799	155,487	196,259	351,746
Group Total	119,884	303,798	423,682	123,868	304,923	428,791

(*) Mainly due to consolidation adjustments

The aforementioned net deferred tax assets of €119.9 million (€123.9 million at 31 December 2024) arise mainly from the Parent Company. These deferred tax assets have been recorded in the consolidated balance sheet because the Parent Company's Board of Directors consider that, based on the best estimate of future results, it is probable that these assets will be fully recovered within a time frame of up to 10 years. In order to determine the estimated future taxable profits that justify this recovery analysis, the following has been used as a starting point:

- Projections of estimated taxable profits corresponding to the Spanish consolidated tax group for the next 5 years (and extrapolated up to 10 years) based on the current product portfolio and structure of the current Group. This projection has taken into account sustained increases in future profits, resulting mainly from expected increases in sales of the Group's product portfolio, as well as significant synergies expected from the optimisation of the Group's structure.
- Estimated additional impacts expected on results in the coming years taking into account the relevant investments made in and prior to financial year 2025. For this purpose, expected target returns, as well as probabilities of success in achieving them, have been considered.
- Finally, it should be noted that on 29 December 2021, Law 22/2021, of 28 December, on the General State Budget for 2022, was published in the Official State Gazette, thereby amending the Corporate Income Tax Law and establishing the concept of "minimum taxation" in Spain (as from 1 January 2022 and for an indefinite period of time). Minimum taxation implies that, depending on the size and type of entity, companies must have a minimum net tax liability (generally set at 15%). In order to determine the net tax liability, a priority is established in the allowances and deductions, so that those of lower priority cannot be deducted if they reduce taxation below the stipulated minimum, and hence they must be deferred. The concept of minimum taxation has implications for the recognition of deductions for the purposes of assessing the recoverability of deferred tax assets.

The sensitivity analysis performed on the projected taxable income (within a +/-5% range of variation) would not result in a significant impact on the consolidated financial statements at 31 December 2025 and 2024.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Most of the unrecorded tax assets recognised in the consolidated balance sheet correspond to the United States, specifically to the subsidiaries Almirall LLC and Almirall Inc. (which are tax consolidated), based on the expectations of local profit for this subsidiary and the associated CGUs (as described in Note 5-d)).

In the case of deductions pending offset, which correspond to the Spanish consolidated tax group, the amount that is expected to be recovered beyond 10 years has not been recognised in the consolidated balance sheet, even though the application limit is 18 years.

Balances held with the Public Administration

The balances receivable from and payable to the Public Administrations, as of 31 December 2025 and 2024, are as follows:

	Thousands of Euros	
	31/12/2025	31/12/2024
Public Treasury (Hacienda) VAT owed	7,342	8,344
Public Treasury (Hacienda) Corporate Income Tax owed	10,086	13,229
Other concepts	31	59
Total debtor balance	17,459	21,632
Public Treasury (Hacienda) VAT paid	9,689	6,181
Personal income tax	4,729	8,845
Social Security Agencies creditors	4,808	4,179
Public Treasury (Hacienda) Corporate Income Tax creditor	11,783	23,306
Total credit balances	31,009	42,511

The corporate income tax receivables are mainly due to the expected tax refund for the scope of consolidation in Spain.

Global minimum complementary tax

In March 2022, the Organisation for Economic Co-operation and Development (OECD) approved its Pillar 2 international taxation model, which establishes a global minimum corporate tax rate of 15% for groups with a turnover of more than €750 million.

The Almirall Group, which heads the Company, is subject to the global minimum complementary tax, following the publication on 21 December 2024 in the Official State Gazette of Law 7/2024, of 20 December, which transposes the European directive to guarantee this global minimum taxation of 15% by approving the new Complementary Tax for tax periods beginning on or after 31 December 2023. Thus, Pillar 2 requires that affected groups calculate their effective tax rate for each jurisdiction in which they operate according to specific rules. Regarding those jurisdictions where the effective rate is below 15%, the Group must pay an additional tax corresponding to the difference between the effective tax rate of the jurisdiction in question and the minimum rate of 15%.

On 23 May 2023, the IASB published an amendment to IAS 12 pertaining to Pillar 2 standards, effective for periods beginning as from 1 January 2023. The amendments to IAS 12 provide a mandatory temporary exemption from recognition of the deferred tax balances arising from the implementation of Pillar 2 legislation.

As of the end of the 2025 financial year, the Group has conducted an analysis of its potential exposure to the income tax arising from Pillar 2; this is based on the application of the Transitional Safe Harbour, concluding that the additional tax provided for in Law 7/2024, of December 20, is not applicable.

24. Business and geographic segments

Segmentation criteria

The main criteria for defining the Group's information by segments in the consolidated financial statements for the years ending on 31 December 2025 and 2024 are explained below.

The business segments listed below are those for which separate financial information is available, and on which the reports are based, and the results of which are reviewed on a monthly basis by the Group's

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Management (Management Committee) for operational decision-making, in order to decide on the resources to be allocated to each segment and evaluate their performance, as well as having discrete financial information available.

Broadly speaking, the Group's Management Committee is divided between the commercial areas (which are those that generate recurring revenue) and the other areas (which do not usually generate revenue and/or provide services to the other areas). The Group's segments are therefore divided into:

- Commercial areas: within this part, three segments are distinguished, in line with what is explained in Note 5-p):
 - i. Marketing through its own network
 - ii. Marketing through its own network (United States)
 - iii. Marketing through licensees
- All other areas: within this part, two segments are distinguished:
 - iv. Research and development
 - v. Corporate and manufacturing services

The reported operating segments are those whose income, results and/or are assets greater than 10% of the corresponding consolidated figure.

The marketing segment through the company's own network is divided geographically (Europe and the United States) according to the specific product portfolio of each region (which is mostly exclusive to each area, except for Klisyri) and market dynamics, which especially in the area of access to prescription medicinal products is very different, as mentioned in the Note 5-q).

Research and development is separated due to being considered a key activity to secure the long-term future of the Group, and it has a significant budget allocation (as a target figure, around 12% of net turnover).

All other activities, essentially support functions such as Human Resources, Information Technology, Finance and Legal, among others, provide services to the rest of the areas and have independent managers in charge of the commercial business units, which is why they are presented separately and aggregated in the Corporate and Manufacturing Services segment. In addition, this segment incorporates the revenue derived from the manufacturing activity for third parties and the intermediation mentioned in Note 5-p) (product sales section), which mainly corresponds to manufacturing for Covis, linked to the contract explained in Note 12. The costs of the production centres are incorporated in the segments of the commercial areas (as a higher cost of Procurement), which is why there is an "Adjustments and reclassifications" column for arriving at the figures presented in the consolidated income statement.

Basis and methodology for reporting by business segments

The following aspects must be taken into account when segmenting the consolidated profit and loss account:

- In the case of the commercial areas, the main allocation criterion is determined by net turnover, such that the expenses allocated to these segments are those that are directly attributable to the products that are marketed under that segment. As mentioned above, this also includes the manufacturing costs incurred at the Group's production plants. In addition, it includes the personnel and other operating expenses of the various business units in each territory, together with amortisation mainly of the intangible assets linked to the licences described in Note 9.
- The financial result is grouped in the Corporate Services and Manufacturing segment, given that the Group's cash management is centralised. Furthermore, the corporate income tax expense is also grouped because the business managers do not manage the results in each tax jurisdiction, with the exception of the US segment, where the business unit coincides with the tax jurisdiction.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

- The information by segments considers the consolidated balances of each segment, therefore attributing the relevant consolidation adjustments to each of the segments and without intercompany transactions.
- The Group does not itemise information about relevant clients by segments in the financial statements, as none of them individually represents more than 10% of the Group's net turnover.

When segmenting the Consolidated Balance Sheet, the following aspects must be taken into account:

- Goodwill and intangible assets are assigned as detailed in the Notes 8 and 9. In particular, goodwill is assigned to marketing through the company's own network (Europe), with the exception of the licensee part of Poli Group's goodwill. In the case of intangible assets associated with business combinations and licensing agreements, the criterion is similar to that for goodwill, with the exception of those agreements where the products are under development, which are classified under the R&D segment. Software is mainly classified in the corporate services and manufacturing segment.
- The assets for rights of use assigned to the segments of Marketing through the company's own network correspond to the leasing contracts for the vehicles and commercial offices of those business units. The HQ contract is assigned to the Corporate Services segment.
- Property, plant and equipment is mostly assigned to the Corporate Services and Manufacturing segment, given that the main properties are the chemical and pharmaceutical plants, with the exception of the R&D centre in Sant Feliu de Llobregat (Barcelona, Spain), which is assigned to the Research and Development segment. Further details of the Group's main properties and their geographical location can be found in Note 11.
- Inventories (finished goods and merchandise) and trade receivables are classified in the segment to which the associated product sales correspond. Raw materials, work in progress and semi-finished goods are classified in the corporate services and manufacturing segment.
- Cash, financial assets (current and non-current) and tax assets (deferred and current) are classified in the Corporate services and manufacturing segment, the latter according to the criterion already explained for the corporate income tax expense.
- In the case of the financial asset with Covis (Notes 12 and 15), it is assigned to the Corporate services and manufacturing segment, in line with revenue, as explained in this Note.
- The Group has not established criteria for the allocation of equity and liabilities by segments and, therefore, it does not itemise this information.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Financial information by segments

Consolidated segmented income statement for the year ending on 31 December 2025:

	Commercial areas			Other areas			Total
	Own network (Europe)	Own network (USA)	Licensees	R & D	Corporate services and manufacturing	Reclassifications	
Net turnover	910,110	45,191	111,494	-	41,289	-	1,108,084
Other Income	-	-	-	2,927	3,521	-	6,448
Operating income	910,110	45,191	111,494	2,927	44,810	-	1,114,532
Work carried out on fixed assets	-	-	-	28,078	-	-	28,078
Supplies	(235,791)	(8,479)	(44,237)	(2,087)	(53,519)	79,564	(264,549)
Staff costs	(97,278)	(16,805)	(1,572)	(37,405)	(67,393)	(43,331)	(263,784)
Depreciation	(69,214)	(26,649)	(8,139)	(8,970)	(25,781)	(12,430)	(151,183)
Net change in valuation adjustments	-	362	-	-	96	-	458
Other operating expenses	(169,275)	(22,876)	(5,940)	(117,692)	(50,716)	(23,803)	(390,302)
Net gains (losses) on disposal of assets	-	-	-	-	(199)	-	(199)
Operating profit	338,552	(29,256)	51,606	(135,149)	(152,702)	-	73,051
Financial income	-	-	-	-	6,848	-	6,848
Financial expenses	-	-	-	-	(16,948)	-	(16,948)
Exchange rate differences	-	-	-	-	(65)	-	(65)
Valuation gain on financial instruments	-	-	-	-	11,562	-	11,562
Earnings before tax	338,552	(29,256)	51,606	(135,149)	(151,305)	-	74,448
Corporate income tax	-	(339)	-	-	(27,955)	-	(28,294)
Net profit for the year attributable to the Parent Company	338,552	(29,595)	51,606	(135,149)	(179,260)	-	46,154

Segmented assets at 31 December 2025:

	Commercial areas			Other areas		Total
	Own network (Europe)	Own network (USA)	Licensees	R & D	Corporate services and manufacturing	
Goodwill	270,550	-	45,416	-	-	315,966
Intangible assets	450,234	144,139	121,457	160,932	17,570	894,332
Right-of-use assets	5,733	1,410	61	-	33,572	40,776
Property, plant and equipment	1,582	4,376	11	40,790	122,105	168,864
Financial assets	-	-	-	-	22,690	22,690
Deferred tax assets	-	-	-	-	180,523	180,523
NON-CURRENT ASSETS	728,099	149,925	166,945	201,722	376,460	1,623,151
Stocks	107,946	9,227	8,438	-	52,521	178,132
Trade and other receivables	95,393	23,286	24,395	12,695	2,701	158,470
Current tax assets	-	-	-	-	17,459	17,459
Other current assets	-	-	-	-	21,103	21,103
Current financial investments	-	-	-	-	1,050	1,050
Cash and cash equivalents	-	-	-	-	337,769	337,769
CURRENT ASSETS	203,339	32,513	32,833	12,695	432,603	713,983
TOTAL ASSETS	931,438	182,438	199,778	214,417	809,063	2,337,134

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Consolidated segmented income statement for the year ending on 31 December 2024:

	Commercial areas			Other areas			Total
	Own network (Europe)	Own network (USA)	Licensees	R & D	Corporate services and manufacturing	Reclassifications	
Net turnover	808,381	55,429	97,226	-	24,685	-	985,721
Other Income	-	-	-	2,938	1,968	-	4,906
Operating income	808,381	55,429	97,226	2,938	26,653	-	990,627
Work carried out on fixed assets	-	-	-	20,354	-	-	20,354
Supplies	(218,246)	(10,496)	(42,734)	(2,095)	(40,539)	75,715	(238,395)
Staff costs	(85,229)	(15,825)	(1,408)	(33,780)	(58,991)	(39,698)	(234,931)
Depreciation	(64,318)	(26,216)	(9,928)	(8,477)	(18,836)	(11,309)	(139,084)
Net change in valuation adjustments	-	166	-	-	(861)	-	(695)
Other operating expenses	(147,351)	(25,216)	(6,106)	(100,203)	(44,681)	(24,708)	(348,265)
Net gains (losses) on disposal of assets	-	(713)	-	(1,713)	(1,068)	-	(3,494)
Impairment losses on property, plant and equipment, intangible assets and goodwill	-	(10,031)	-	-	-	-	(10,031)
Operating profit	293,237	(32,902)	37,050	(122,976)	(138,323)	-	36,086
Financial income	-	-	-	-	7,652	-	7,652
Financial expenses	-	-	-	-	(15,658)	-	(15,658)
Exchange rate differences	-	-	-	-	(1,105)	-	(1,105)
Valuation gains on financial instruments	-	-	-	-	(477)	-	(477)
Earnings before tax	293,237	(32,902)	37,050	(122,976)	(147,911)	-	26,498
Corporate income tax	-	(2,970)	-	-	(13,381)	-	(16,351)
Net profit for the year attributable to the Parent Company	293,237	(35,872)	37,050	(122,976)	(161,292)	-	10,147

Segmented assets at 31 December 2024:

	Commercial areas			Other areas		Total
	Own network (Europe)	Own network (USA)	Licensees	R & D	Corporate services and manufacturing	
Goodwill	270,550	-	45,416	-	-	315,966
Intangible assets	482,698	171,255	137,675	126,944	18,395	936,967
Right-of-use assets	6,600	2,220	70	-	34,696	43,586
Property, plant and equipment	1,434	6,009	14	28,300	118,033	153,790
Financial assets	-	-	-	-	16,350	16,350
Deferred tax assets	-	-	-	-	188,860	188,860
NON-CURRENT ASSETS	761,282	179,484	183,175	155,244	376,334	1,655,519
Stocks	118,350	8,125	4,673	-	40,635	171,783
Trade and other receivables	68,979	22,403	28,669	25,104	6,289	151,444
Current tax assets	-	-	-	-	21,632	21,632
Other current assets	-	-	-	-	18,987	18,987
Current financial investments	-	-	-	-	201	201
Cash and cash equivalents	-	-	-	-	377,097	377,097
CURRENT ASSETS	187,329	30,528	33,342	25,104	464,841	741,144
TOTAL ASSETS	948,611	210,012	216,517	180,348	841,175	2,396,663

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

Additions to non-current assets by segments during the six months ending 31 December 2025 and 2024:

	Thousands of euros	
	31/12/2025	31/12/2024
Own network (Europe)	57,260	79,486
Own network (USA)	220	557
Licensees	-	-
R & D	52,416	40,562
Corporate services and manufacturing	35,005	17,181
Total additions	144,901	137,786

25. Dividends paid by the Parent Company

The dividends paid by the Parent Company during fiscal years 2025 and 2024, which in both cases corresponded to the dividends approved on the results of the previous year, are shown below:

	2025			2024		
	% of nominal	Euros per share	Amount (Thousands of Euros)	% of nominal	Euros per share	Amount (Thousands of Euros)
Ordinary shares	158%	0.19	40,559	158%	0.19	39,785
Total Dividends paid	158%	0.19	40,559	158%	0.19	39,785

The 2025 and 2024 dividend payments have been implemented as a flexible dividend in which shareholders have been offered the choice between receiving newly issued shares of the Parent Company or the cash amount equivalent to the dividend.

In 2025, the cash payment was chosen by 66.7% of the holders of rights (which meant a disbursement of €26.2 million), and the remaining 33.3% opted to receive new shares, each at par value, which were issued as a capital increase (Note 16).

In 2024, the cash payment was chosen by 8.5% of the holders of rights (which meant a disbursement of €3.3 million), while the remaining 91.5% opted to receive new shares, each at par value, which were issued as a capital increase (Note 16).

When a dividend is approved, which may be settled in cash or through the issue of fully paid-up shares at the investor's option, i.e., remuneration with shares for a specific value, the corresponding liability must be recognised with a charge to reserves equivalent to the fair value of the rights to be allotted shares at no charge. If the investor opts to subscribe for fully paid-up shares, then the corresponding capital increase will be recognised. If the investor elects to collect the dividend, then the liability will be derecognised with a credit to the cash paid.

26. Basic earnings / (loss) per share

Basic earnings per share is calculated by dividing the net profit for the period that can be attributed to the Parent Company by the weighted average number of ordinary shares outstanding during the period, excluding the average number of treasury shares held for the entire period. Diluted earnings per share are calculated by dividing the net profit for the period attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period, adjusted by the weighted average number of ordinary shares that would be issued if all potential ordinary shares were converted into ordinary shares of the Parent Company. For these purposes, the conversion is deemed to take place at the start of the period or at the moment of issue of the potential ordinary shares if these have been issued during the period itself.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

As of 31 December 2025 and 2024, there were no financial instruments with dilutive effects. Accordingly:

	2025	2024
Net result of the year (thousands of euros)	46,154	10,147
No. of weighted average ordinary shares available (*)	213,996	213,996
No. of weighted average diluted shares (**)	213,996	213,996
Basic earnings per share (euros)	0.22	0.05
Diluted earnings per share (euros)	0.22	0.05

(*) Number of issued shares minus treasury shares

(**) Average number of available ordinary shares

As described in Note 16, during 2025 a total of 1,316,480 new shares of the Parent Company were created in the capital increase on 11 June 2025. During 2024, as a result of the increase in the fully-paid share capital through which the flexible dividend programme was implemented, a total of 4,074,994 new shares of the Parent Company were created in the capital increase through a bonus issue on 12 June 2024.

In accordance with the provisions of IAS 33, these capital increases have been taken into account in the earnings per share for 2024, whose value matches what was published in the consolidated financial statements for the year ended 31 December 2024.

Lastly, the calculation of diluted consolidated earnings per share takes into account the consolidated profit for the year attributable to the Parent Company, excluding the expense incurred by financial instruments convertible into shares, net of the related tax effect, if any.

27. Commitments, contingent liabilities and contingent assets

a) Commitments

As a result of the research and development activities carried out by the Group, as of the close of fiscal years 2025 and 2024, firm agreements had been entered into for the performance of these activities for the amount of €94.6 million and €74.5 million, respectively, and in future years these agreements will have to be honoured.

As of 31 December 2025, the Group has set up various guarantees with the public administration and third parties in the amount of €19.5 million at 31 December 2025 (€15.1 million at 31 December 2024).

As of 31 December 2025 and 2024, there were , no significant commitments to purchase property, plant and equipment.

The Group's lease commitments are described in Note 10.

b) Contingent liabilities

There are no contingent liabilities other than those mentioned in the notes to these consolidated financial statements (payments related to the acquisition of intangible assets, Note 9).

c) Contingent assets

As at 31 December 2025 and 2024, there are no contingent assets.

28. Transactions with related parties

Transactions between the Parent Company and its subsidiaries, since they are related parties, have been removed during the consolidation process and are not disclosed in this note. Transactions between the Parent Company and its subsidiaries are itemised in the individual financial statements.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

During 2025 and 2024, Group companies have carried out the following transactions with related parties, consequently maintaining the following balances at 31 December 2025 and 2024:

Company	Related party	Concept	Year	Thousands of Euros		
				Transactions	Balances - Debtor / (Creditor)	
				Transactions - Income/(Expenses)	Commercial	Lease liabilities
Almirall, S.A.	Sinkasen, S.L.U.	Leases	2025	(3,389)	-	(25,320)
			2024	(3,293)	-	(28,188)
Almirall, S.A.	Sinkasen, S.L.U.	Rebilling of works	2025	527	399	-
			2024	129	126	-
Almirall, S.A.	Grupo Corporativo Landon, S.L.	Others	2025	-	(35)	-
			2024	(49)	(49)	-

The headquarters of the Group (Note 10) is leased to Sinkasen S.L.U, a related entity whose sole shareholder is Grupo Corporativo Landon, S.L. The lease agreement was renewed in January 2023 for a period of ten years, until 31 December 2032.

Additionally, companies linked to some members of the Board of Directors have provided advisory services to the Parent Company for amounts of €17,000 and €24,000 in 2025 and 2024, respectively. The Board of Directors believes that these services do not compromise its independence, given that they are one-off and non-significant amounts, received in the capacity of experts on the subject matter.

Transactions with related parties are carried out at market price.

29. Remuneration of the Board of Directors and Senior Management

The amount accrued during fiscal years 2025 and 2024 by current and former members of the Parent Company's Board of Directors for all remuneration items (salaries, bonuses, allowances, remuneration in kind, life insurance, compensation, incentive schemes and social security contributions) amounted to €3,133 and €2,858 thousand, respectively. There are life insurance policies accrued in the amount of €3 thousand in 2025 (€3 thousand in 2024).

During fiscal year 2025, civil liability insurance premiums in the amount of €218 thousand (€230 thousand in 2024) have accrued to cover members of the Board of Directors and Senior Management for possible damages caused in the performance of their duties.

In addition, the remuneration, paid and unpaid, accrued by the Parent Company's Board of Directors from multi-year incentive and loyalty plans and the SEUS and PSP Plans (see Note 5-t)), amounted to €1,203 thousand in 2025 (€739 thousand in 2024). The balance of the provision for these plans amounts to €2,063 thousand in 2025 (€1,094 thousand in 2024).

As of 31 December 2025 and 2024, there are no other pension commitments agreed with current and former members of the Parent Company's Board of Directors.

The Group has included, as Senior Management, members of the Management Board who are not on the Board of Directors for the purposes of the consolidated financial statements.

The amount accrued during fiscal years 2025 and 2024 by members of Senior Management who are not members of the Parent Company's Board of Directors, for all remuneration items (salaries, bonuses, allowances, remuneration in kind, compensation, incentive schemes and social security contributions), came to €5,175 thousand and €6,196 thousand, respectively. There are life insurance policies accrued in the amount of €15 thousand in 2025 (€17 thousand in 2024).

In addition, the remuneration accrued, both paid and unpaid, by members of Senior Management of the Group under the multi-year incentive and loyalty schemes, the SEUS Plan and the PSP amounted to €2,072 thousand and €1,502 thousand in fiscal years 2025 and 2024, respectively. The balance of the provision for these plans amounts to €4,405 thousand in 2025 (€4,179 thousand in 2024).

There are no other pension commitments contracted with Senior Management at 31 December 2025 and 2024.

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

The members of the Board of Directors and of Senior Management of the Group have not received any shares or share options during fiscal years 2025 and 2024, nor have they exercised any options or do they have any options outstanding, nor have they been granted any advances or loans.

30. Other information concerning the Board of Directors

In order to avoid situations of conflict of interests with the Parent Company, during fiscal years 2025 and 2024, the directors who have held positions on the Board of Directors have complied with the obligations set forth in Art. 228 of the revised text of the Spanish Capital Companies Act. Likewise, they themselves and the people related to them have refrained from incurring in the scenarios of conflict of interest set forth in Art. 229 of that law, except in those cases in which the corresponding authorisation has been obtained.

31. Environmental information

The Group companies have adopted the appropriate measures in environmental matters in order to comply with the current environmental legislation. The Group's strategy takes into consideration the Paris Agreement goals of limiting global temperature increase to below 2°C and climate neutrality by 2050. The impact of climate change risk has not been considered relevant in the preparation of the consolidated financial statements for 2025, given that it does not significantly affect the useful lives of assets and/or asset impairment assessments and no legal or constructive obligations arise for the Group.

The Group's property, plant and equipment includes certain assets for environmental protection (limitation of fumes, subsoil drainage, etc.), with a carrying value of €19.4 million on 31 December 2025 (€14.9 million on 31 December 2024). In addition, investments in the amount of €4.2 million were made during 2025 (€3.3 million in 2024).

The consolidated income statements for fiscal years 2025 and 2024 include expenses related to environmental protection for the amounts of €2.2 million and €2.1 million, respectively.

The Group has made investments for an amount of €1,419 thousand related to photovoltaic panels intended for the production of electricity for self-consumption in 2025, the carrying value of which amounts to €4,748 thousand as of 31 December 2025 (€3,483 thousand as of 31 December 2024). The consolidated income statement for 2025 includes expenses related to the maintenance of these panels, which amount to €6 thousand (€6 thousand in 2024), and related depreciation expenses that amount to €235 thousand (€147 thousand in 2024), while the electricity tax expenses in 2025 and 2024 are nil.

The Parent Company's Board of Directors considers that the measures adopted adequately cover all possible needs, and hence there are no environmental risks or contingencies. Accordingly, no subsidies or income related to these activities have been received.

32. Financial risk exposure and capital management

The Group's activities are exposed to various financial risks: market risk (including exchange rate risk, interest rate risk and price risk), credit risk and liquidity risk. The Group's global risk management program contemplates the uncertainty of financial markets, and seeks to minimise the potential adverse effects on its financial profitability.

The management of financial risk is controlled by the Group's Treasury department, which identifies, assesses and hedges financial risks in accordance with the policies approved by the Board of Directors, which provides written policies for overall risk management, as well as for specific areas such as exchange rate risk, interest rate risk, liquidity risk, the use of derivatives and non-derivatives and the investment of excess liquidity.

Interest rate risk

As of 31 December 2025, most of the Group's debt is at a fixed rate, which minimises the risk of a possible increase in interest rates. As described in Note 18, the main debt instruments are as follows:

- On 27 March 2019, the Parent Company arranged a loan facility with the European Investment Bank (EIB) for up to €120 million to fund its research and development efforts, with the objective of providing cutting-edge innovation and differentiated therapies in the area of medical

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

dermatology. The first tranche of €80 million was granted on 17 April 2019 at a fixed interest rate of 1.35%, with 32 equal repayments of principal between 17 July 2021 and 17 April 2029, with the latter date being the final maturity. Due to the issue of new debt, the interest rate increased by 0.30%, and therefore the interest rate is 1.65%.

- On 17 December 2025, the Parent Company proceeded to conclude and disburse an issuance of senior unsecured bonds for an aggregate nominal amount of €250 million at a fixed annual interest rate of 3.75%, maturing on 15 June 2031.
- Finally, the Group has taken out a revolving credit facility for the maximum amount of €275 million, which accrues interest at a variable rate tied to the Euribor, but at 31 December 2025 and 2024, it had not drawn down any amounts.

Exchange rate risk

The Group is exposed to the exchange rate risk in certain transactions derived from its activity, and it analyses the forecasts of inflows and outflows in foreign currency on a monthly basis, as well as the changes in and trend of those forecasts. This exchange rate risk is mainly related to cash inflows in dollars for sales of finished product; cash inflows and outflows derived from the transaction with Covis; outflows in dollars for the licensing agreements with Athenex, Lily or Sun Pharma; outflows in dollars for clinical trials; purchases of raw materials and royalty payments in yen and dollars. The most relevant foreign currency in which the Group operates is the US dollar.

Liquidity risk

The Group determines its cash requirements using two fundamental forecasting tools that operate according to different time frames.

On the one hand, a monthly cash budget is established for one year, based on the forecast financial statements for the current year, and deviations from the forecast are analysed on a monthly basis.

And on the other hand, medium- and long-term liquidity planning and management is based on the Group's Strategic Plan, which covers a five-year time frame.

Cash surpluses in foreign currencies are invested in deposits when payments are expected to be made in that currency, mainly US dollars.

The financing instruments include a series of covenants that, in the event of default, could result in a demand for immediate payment of these financial liabilities. The Group periodically assesses fulfilment therewith (as well as expected fulfilment, so that it may take corrective measures, if necessary). As of 31 December 2025 and 2024, all covenants are considered to be fulfilled, as mentioned in Note 18.

The Group manages liquidity risk prudently, maintaining sufficient cash and marketable securities, as well as arranging committed credit facilities for an amount sufficient to support expected needs.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

The table below presents an analysis of the Group's financial liabilities that are settled on a net basis, grouped according to maturity dates for the remaining period, from the balance sheet date to the contractual maturity date. The amounts shown in the table correspond to contractual undiscounted cash flows. Balances payable within 12 months are equal to their carrying amounts, since the effect of the discounting is negligible.

(Thousands of Euros)	Less than 1 year	Between 1 and 2 years	Between 2 and 5 years	More than 5 years
At 31 December 2025				
Loans with credit institutions (Note 18)	10,675	10,675	16,013	-
Financial derivatives held for trading (Note 18)	2,833	-	-	-
Bonds (Note 18)	9,375	9,375	28,125	253,906
Lease liabilities (Note 10)	7,775	7,478	17,264	9,766
Trade and other payables (Note 19)	193,853	-	-	-
Total	224,511	27,528	61,402	263,672
At 31 December 2024				
Loans with credit institutions (Note 18)	10,675	10,675	25,065	-
Financial derivatives held for trading (Note 18)	2,046	-	-	-
Bonds (Note 18)	6,375	304,781	-	-
Lease liabilities (Note 10)	7,061	7,235	17,010	13,276
Trade and other payables (Note 19)	186,525	-	-	-
Total	212,682	322,691	42,075	13,276

Estimate of the fair value

The valuation of assets and liabilities measured at fair value must be itemised by levels, according to the following hierarchy determined by IFRS 13:

- Level 1. Quoted prices (unadjusted) in active markets for identical assets and liabilities.
- Level 2. Data other than the quoted market prices included in Level 1 that are observable for the asset or liability, both directly (i.e., prices) and indirectly (i.e., derived from prices).
- Level 3. Data for the asset or liability that is not based on observable market data.

At 31 December 2025 and 2024, the Group only has assets measured at level 3 fair value, which corresponds to the financial asset with Covis (Notes 12 and 15) and at level 2, which corresponds to the derivative described in Note 18.

Credit risk

The Group manages credit risk through an individual analysis of the items included in accounts receivable. As a preventive measure, credit limits are established for sales to wholesalers, pharmacies and local licensees. In the case of hospital sales, given their minor significance, payment is collected afterwards, once the debt is due.

Amounts considered to be bad debts, once all the pertinent collection procedures have been carried out, are impaired at 100%. The breakdown by maturity, as well as the amounts impaired at year-end 2025 and 2024, are detailed in Note 15.

The Group does not have a significant credit risk, since it invests cash and arranges derivatives with highly solvent entities.

Capital management

The Group manages its capital to ensure the continuity of the activities of the Group companies of which it is the Parent Company and, at the same time, to maximise shareholder returns through an optimal balance between debt and equity.

The Group periodically reviews its capital structure in accordance with a five-year strategic plan that sets the guidelines for investment and financing needs.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

The leverage ratios as of 31 December 2025 and 2024 are as follows:

Thousands of Euros	31 December 2025	31 December 2024
Financial debts (Note 18)	283,691	347,366
Retirement benefit obligations (Note 20)	52,109	58,581
Cash and cash equivalents (Note 12)	(337,769)	(377,097)
Net debt	(1,969)	28,850
Equity (Note 16)	1,487,134	1,488,382
Share Capital (Note 16)	25,774	25,616
Leverage ratio⁽¹⁾	-0.1%	1.9%

(1) Based on the calculation used by the Group to determine the leverage ratio (excluding the amount of "Other financial liabilities" included in Note 19 and the lease liabilities included in Note 10).

Macroeconomic and geopolitical risks

The Group's operations can be conditioned by economic cycles and international geopolitical conflicts, whether in areas in which it operates directly or in territories that impact other activities (such as the supply chain or clinical trials, for example). However, the pharmaceutical sector is generally considered counter-cyclical, given that chronic and prescription treatments tend to have stable demand and do not benefit (or are not harmed) by favourable macroeconomic scenarios (or recession, in the latter case).

In 2025, the Group closely monitored developments in the geopolitical and trade environment, paying particular attention to the new tariff policies implemented by the United States. These measures have included the imposition of additional tariffs on pharmaceutical and chemical intermediates of Chinese origin, as well as the introduction of a universal 10% tariff on most imports, excluding those from USMCA countries.

As at 31 December 2025, the direct and indirect potential impact of these measures has been assessed, thereby concluding that the tariff policies have not had, nor is it foreseen that they will have, a significant impact on the Group's operations or strategy and that they do not affect the fair value of its financial assets or liabilities as at the reporting date.

33. Information on deferrals of payments to suppliers

The periods for payments to suppliers achieved by the Spanish companies of the Group's scope of consolidation comply with the limits established in Law 15/2010, of 5 July, amending Law 3/2004 on combating late payment in commercial transactions. This Law establishes a payment deadline of 60 days.

The itemisation of payments for commercial transactions made during the year and those pending payment at year-end, in relation to the maximum legal deadlines provided for in Law 15/2010, which is itemised pursuant to the Official State Gazette published on 4 February 2016, is as follows:

	2025	2024
	Days	Days
Average period of payment to suppliers	43	42
Ratio of paid transactions	44	44
Ratio of transactions pending payment	26	29
Total payments made	644,696	598,908
Total payments due	31,779	73,126

This balance refers to the suppliers of the Spanish companies of the consolidable group, which, by their nature, are trade payables for debts with suppliers of goods and services.

Finally, in accordance with Law 18/2022 of 28 September, the monetary volume and number of invoices paid in a period lower than the maximum established in the regulations on late payment and the percentage they represent of the total invoices and payments, according to the provisions of the Official

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Notes to the Consolidated Financial Statements
for the year ending on 31 December 2025
(Thousands of euros)

State Gazette published on 29 September 2022, are detailed below for the Spanish companies in the Group's consolidation scope:

	2025		2024	
	Thousands of Euros	Number of invoices	Thousands of Euros	Number of invoices
Invoices paid within the deadline*	508,606	295,473	489,952	30,960
Total invoices paid	644,696	306,139	598,908	36,418
% paid within the deadline*	78.9%	96.5%	81.8%	85.0%

* in accordance with Spanish default regulations

34. Subsequent events

On 20 February 2026, the Board of Directors of Almirall, S.A. has resolved to propose to the General Meeting of Shareholders the distribution of a dividend charged to unrestricted reserves for the amount of €40.8 million (equivalent to €0.19 per share). For the purposes of this dividend distribution, it is proposed to once again utilise the "Flexible Dividend" shareholder remuneration system, already applied in 2025.

Almirall, S.A. and Subsidiaries (Almirall Group)

APPENDIX: INFORMATION ON GROUP COMPANIES

Name	Thousands of Euros					
	Laboratories Almirall S.L.	Laboratorios Tecnobio S.A.	Industrias Farmacéuticas Almirall S.A.	Ranke Química S.A.	Almirall Holding Iberia S.L.	Almirall - Productos Farmacéuticos. Lda.
Address	Spain	Spain	Spain	Spain	Spain	Portugal
Activity	Intermediation services	Inactive	Manufacturing of specialities	Manufacture of raw materials	Holding	Pharmaceutical laboratory
31 December 2025						
Fraction of capital held:						
- Directly	100%	100%	100%	100%	100%	-
- Indirectly	-	-	-	-	-	100%
% voting rights	100%	100%	100%	100%	100%	100%
Consolidation method	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation
Capital	120	61	1,200	1,200	52,602	1,500
Reserves	1,852	347	42,952	20,907	28,668	3,208
Net profit/(loss) for the year	588	4	4,133	1,814	8,369	301
31 December 2024						
Fraction of capital held:						
- Directly	100%	100%	100%	100%	100%	-
- Indirectly	-	-	-	-	-	100%
% voting rights	100%	100%	100%	100%	100%	100%
Consolidation method	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation
Capital	120	61	1,200	1,200	52,602	1,500
Reserves	1,138	318	43,269	21,442	(22,495)	2,914
Net profit/(loss) for the year	714	29	4,643	1,471	73,163	294

Note: All information concerning the indicated companies is obtained from the individual financial statements of the different companies. For this reason, they do not reflect the effect that would result from applying consolidation criteria for the shares. Inactive companies other than those consolidated are not included.

Almirall, S.A. and Subsidiaries (Almirall Group)

APPENDIX: INFORMATION ON GROUP COMPANIES

	Thousands of Euros					
	Almirall, NV	Almirall, BV	Almirall Europa Derma S.L.	Almirall SP. Z.O.O.	Almirall GmbH	Almirall, AG
Name	Belgium	Netherlands	Spain	Poland	Austria	Switzerland
Address	Pharmaceutical laboratory	Pharmaceutical laboratory	Inactive	Intermediation services	Intermediation services	Pharmaceutical laboratory
Activity						
31 December 2025						
Fraction of capital held:						
- Directly	0.01%	-	100%	-	100%	100%
- Indirectly	99.99%	100%	-	100%	-	-
% voting rights	100%	100%	100%	100%	100%	100%
Consolidation method	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation
Capital	1,203	4,000	61	12	36	901
Reserves	2,742	4,318	181	1,723	276	8,441
Net profit/(loss) for the year	204	317	3	72	384	634
31 December 2024						
Fraction of capital held:						
- Directly	0.01%	-	100%	-	100%	100%
- Indirectly	99.99%	100%	-	100%	-	-
% voting rights	100%	100%	100%	100%	100%	100%
Consolidation method	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation
Capital	1,203	4,000	61	12	36	901
Reserves	2,569	3,986	176	1,646	1,845	6,857
Net profit/(loss) for the year	172	332	5	55	430	1,113

Note: All information concerning the indicated companies is obtained from the individual financial statements of the different companies. For this reason, they do not reflect the effect that would result from applying consolidation criteria for the shares. Inactive companies other than those consolidated are not included.

Almirall, S.A. and Subsidiaries (Almirall Group)

APPENDIX: INFORMATION ON GROUP COMPANIES

Name	Thousands of Euros					
	Almirall Limited	Almirall, S.A.S.	Almirall SpA	Almirall Hermal GmbH	Almirall Inc	Subgroup (1) Almirall LLC
Address	United Kingdom	France	Italy	Germany	United States	United States
Activity	Pharmaceutical laboratory	Pharmaceutical laboratory	Pharmaceutical laboratory	Pharmaceutical laboratory	Holding	Pharmaceutical laboratory
31 December 2025						
Fraction of capital held:						
- Directly	-	-	-	100%	100%	-
- Indirectly	100%	100%	100%	-	-	100%
% voting rights	100%	100%	100%	100%	100%	100%
Consolidation method	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation
Capital	571	12,527	8,640	25	-	-
Reserves	13,866	8,924	2,902	38,452	212,398	223,177
Net profit/(loss) for the year	983	2,046	3,526	36,482	(24,887)	(33,558)
31 December 2024						
Fraction of capital held:						
- Directly	-	-	-	100%	100%	-
- Indirectly	100%	100%	100%	-	-	100%
% voting rights	100%	100%	100%	100%	100%	100%
Consolidation method	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation
Capital	571	12,527	8,640	25	-	-
Reserves	13,812	7,205	6,398	32,893	273,387	291,806
Net profit/(loss) for the year	865	1,721	4,504	34,662	(34,410)	(41,122)

(1) Includes Aqua Pharmaceutical Holdings Inc. and Almirall LLC holding companies

Note: All information concerning the indicated companies is obtained from the individual financial statements of the different companies. For this reason, they do not reflect the effect that would result from applying consolidation criteria for the shares. Inactive companies other than those consolidated are not included.

Almirall, S.A. and Subsidiaries (Almirall Group)

APPENDIX: INFORMATION ON GROUP COMPANIES

Name	Thousands of Euros					
	Almirall Aps	Poli Group Holding S.R.L.	Polichem, S.A.	Polichem S.R.L.	Almirall AS	Almirall AS
Address	Denmark	Italy	Luxembourg Switzerland/China	Italy	Norway	Sweden
Activity	Pharmaceutical laboratory	Holding	Pharmaceutical laboratory	Pharmaceutical laboratory	Intermediation services	Intermediation services
31 December 2025						
Fraction of capital held:						
- Directly	100%	100%	-	0.4%	100%	100%
- Indirectly	-	-	100%	99.6%	-	-
% voting rights	100%	100%	100%	100%	100%	100%
Consolidation method	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation
Capital	17	31	1,447	540	27	2
Reserves	3,681	20,320	24,478	771	492	578
Net profit/(loss) for the year	446	39,374	25,690	2,756	32	106
31 December 2024						
Fraction of capital held:						
- Directly	100%	100%	-	0.4%	100%	100%
- Indirectly	-	-	100%	99.6%	-	-
% voting rights	100%	100%	100%	100%	100%	100%
Consolidation method	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation	Full consolidation
Capital	17	31	1,447	540	27	2
Reserves	3,438	6,682	23,153	779	473	518
Net profit/(loss) for the year	248	238,637	36,375	1,991	22	25

Note: All information concerning the indicated companies is obtained from the individual financial statements of the different companies. For this reason, they do not reflect the effect that would result from applying consolidation criteria for the shares. Inactive companies other than those consolidated are not included.

APPENDIX: INFORMATION ON GROUP COMPANIES

Name	Thousands of Euros		
	Almirall S.r.o.	Almirall S.r.o.	Almirall (Shanghai) Pharmaceutical Consulting Co., Ltd.
Address	Czech Republic	Slovak Republic	China
Activity	Intermediation services	Intermediation services	R&D services
31 December 2025			
Fraction of capital held:			
- Directly	100%	100%	100%
- Indirectly	-	-	-
% voting rights	100%	100%	100%
Consolidation method	Full consolidation	Full consolidation	Full consolidation
Capital	-	5	119
Reserves	600	583	-
Net profit/(loss) for the year	52	(6)	-
31 December 2024			
Fraction of capital held:			
- Directly	100%	100%	-
- Indirectly	-	-	-
% voting rights	100%	100%	-
Consolidation method	Full consolidation	Full consolidation	-
Capital	-	5	-
Reserves	536	573	-
Net profit/(loss) for the year	40	24	-

Note: All information concerning the indicated companies is obtained from the individual financial statements of the different companies. For this reason, they do not reflect the effect that would result from applying consolidation criteria for the shares. Inactive companies other than those consolidated are not included.